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PREFACE
The intention of this report is to document the development of a rapid method for deter-
mining microbial susceptibilities to antibiotics by use of the firefly luciferase ATP assay.
The progress and results of the studies involved, including developmental decisions and
raw data, are recorded chronologically in report form from the inception of the project
through completion of efforts in 1975. The studies were conducted at the Tufts-New Eng-
land Medical Center Hospital (NEMCH) in Boston under a cooperative agreement with God-
dard Space Flight Center (GSFC), National Aeronautics and Space Administration (NASA).
Laboratory and clinical results from this research have been summarized and presented at
annual meetings of the American Society for Microbiology (Vellend et al., 1974; Schrock
et al., 1975; Schrock et al., 1976) and published in the form of a NASA X-document
(Picciolo et al., 1976). Appropriate patent applications have been filed in the U.S. Patent
Office (Chappelle et al., Schrock et al., Picciolo et al.).
Further modifications, refinements, and clinical testing of procedures for detection of
bacteriuria as well as determinations of antibiotic susceptibilities have continued at the
Hahnemann Medical College and Hospital (HMCH) in Philadelphia, under a contract with
NASA/GSFC. The major thrust of ongoing research centers on the development of filtra-
tion alternatives to centrifugation steps, reducing time and manipulations required in
procedures as developed at NEMCH. HMCH results have been presented at various scientific
meetings and conferences (Gutekunst, 1975;Gutekunst, 1977, Gutekunst, Jaffee
et al., 1976; McGarry and Chappelle, 1976; Jaffee et al., 1976; Gutekunst, Picciolo et al.,
1976; Deming et al., 1977; Gutekunst et al., 1977) and will be summarized in a future
NASA X-document.
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APPLICATION OF FIREFLY LUCIFERASE ASSAY
FOR ADENOSINE TRIPHOSPHATE (ATP) TO
ANTIMICROBIAL DRUG SENSITIVITY TESTING
H. Vellend, S. Turtle, C. G. Schrock, J. W. Deming,
M. Barza, and L. Wienstein
New England Medical Center Hospital
Boston, Massachusetts
G. L. Picciolo and E. W. Chappelle
Goddard Space Flight Center
Greenbelt, Maryland
INTRODUCTION
The objective of the research to be described was to develop and evaluate a rapid method
for the determination of microbial susceptibility to antibiotics using the firefly luciferase
assay for adenosine triphosphate (ATP) as an indicator of antibiotic effect. The research
was a direct outgrowth of an effort by National Aeronautics Space Administration to develop
methods for detecting extraterrestrial life. In the 1960's, investigations undertaken by the
Space Biology Branch of'Goddard Space Flight Center (GSFC) had the following objectives:
• The determination of a parameter whose presence or absence would be a
relatively universal indicator of life forms
• The development of techniques for the detection of this parameter in the
presence of'intertenng substances
• The automation of these techniques so that the assay could be performed with
high reliability in remote locations
The parameter chosen as a relatively universal indicator of life forms was the presence of
ATP. The ubiquity and functional significance of ATP in metabolism allows its assay to
be an excellent monitor of the biological mass of a specimen. Because the firefly luciferase
bioluminescence reaction is specific for ATP, many investigators have used this reaction to
determine the amount of bacteria or biological mass in a specimen. (Beutler and Mathau,
1967; Brewer and Knutsen, 1966; Cole et al., 1967; Ebadi et al., 1971; Freese et al., 1969;
Holm-Hansen and Booth, 1966; Lee et al., 1971; Patterspn et al., 1970).
The reaction mechanism and kinetics have been determined by several investigators (McElroy
et aL, 1969; Strehler and McElroy, 1968). The reaction can-be summarized in two steps
(Plant etal., 1968):
E + LH2 + ATP— - — «~E • LHf • AMP + PP
E • LH2 • AMP + Oj-^-Oxyluciferin + C02 + AMP + hi>
where E = firefly luciferast
LH2 = reduced luciferin
ATP = adenosine triphosphate
E • LH2 • AMP = luciferase-luciferyl-adenylate complex (active intermediate)
Oxyluciferin = luciferin (oxidized state)
PP = pyrophosphate
AMP = adenosine-5' monophosphate
hJ> = Kght(550nm)
Conditions have been prescribed where this enzymatic reaction can be used as a rapid, sensi-
tive, and simple assay for the quantitation of bacteria (Chappelle and Levin, 1964). Several
methods for the extraction of ATP from bacterial cells were developed (Chappelle and
Levin, 1968; Klofat et al., 1969; Macleod et aL, 1969). When all reagents are present in ex-
cess, the light production is proportional to the ATP concentration, which is in turn propor-
tional to the bacterial cell concentration in the specimen. The plot of bacterial cell concen-
tration versus light units shows a linear response over a functional range (Chappelle and
Levin, 1968).
The average ATP content of a wide variety of bacterial species is 2.5 X 10"10 Mg per organism.
The ATP content varies somewhat through a growth cycle (Freese et al., 1969; Klofat et
al., 1969) and varies with species from 0.28 to 8.9 X 10"10 ng per organism for the 19
species tested (Chappelle and Levin, 1968; Seliger, 1973).
One of the major problems in determining the relationship between ATP levels and bacterial
cell numbers is the presence of significant amounts of soluble ATP and cellular ATP of non-
bacterial origin in the sample under consideration. To isolate bacterial cells for assay, a meth-
od was; developed to chemically remove the ATP associated with nonbacterial cells as well
as any soluble ATP from a specimen (Picciolo et al., 1971). The specimen is treated with
a nonionic detergent that selectively lyses mammalian cells but does not disturb the cell
membranes of bacteria. An ATPase that hydrolyzes all the free ATP is added. The reaction
is then inhibited, the bacteria are lysed, and their ATP content assayed by the luciferase
bioluminescent reaction.
Potential biomedical applications of the ATP assay technology have been investigated by
the Space Biology Branch and more recently the Instrument Branch of GSFC. In 1969,
studies were undertaken to evaluate the ATP assay for the rapid detection of bacteria in
urine and a prototype automated instrument was developed (Picciolo et al., 1971). Initially,
over 700 urine specimens were assayed for bacteria by using both the ATP method and
standard colony counting on agar plates. While the ATP method always gave positive results
when the urine specimen contained greater than 10,000 bacteria/ml (a number generally
considered to be clinically significant (Kass, 1956)), this method often gave values which
corresponded to much higher bacterial counts than those obtained by plate counting. How-
ever, the quantitative correlation was significantly improved with refinements in the methods
of eliminating nonbacterial ATP and by increasing the operational sensitivity of the reaction
by concentration of the bacteria from the urine specimen. Randomly selected results from
recent studies are shown in table 1. Investigations as to the sources of the discrepancies
still seen between the ATP method and viable colony counting are currently in progress.
Table 1
Bacterial Count per ml from Clinical Urine Specimens
Comparing the Luciferase Centrifugation Procedure
with the Agar Pour Plate Method
Specimen
Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Luciferase
Bacteria per ml
3.2 x 108
3.1 « 104
<103
<103
7. 0 x 103
<103
9 4 x 103
<103
3.1x 107
3 1 x 107
<103
2 7 x 104
8.4 x 107
3 2 x 104
2 1 x 1C8
1 3 x 107
1 6 x 1C7
8 6 x 104
<103
2.4 x 104
g
3 1 x 10
5 5 x 103
Pour Plate
Colony Count
>107
4x 103
<102
8x 103
1 x 105
<102
2 x 102
<102
>107
>107
<102
<io2
>107
9 x 102
8 x 106
1 x 107
>107
4x 104
1 x 102
<102
e
5 x 106
1 x 103
Following a review of this work by the National Academy of Engineering's Committee on
the Interplay of Engineering with Biology and Medicine, Dr. David Rutstein of the Harvard
School of Public Health recommended that this technology be applied to the rapid determi-
nation of microbial susceptibility to antibiotics. A collaborative proposal for this purpose
was drawn up by GSFC and the New England Medical Center Hospital, Boston Massachusetts.
The progress and results of these studies are the substance of this document. A final summary
of initial studies using pure bacterial cultures as opposed to clinical samples is included as
Appendix A.
Optimum use of antimicrobial agents to combat infection depends upon knowledge of the
susceptibility of the infecting organism. Although susceptibility can sometimes be predicted
from the general behavior of the bacterial species involved, the most reliable approach is
generally that of direct measurement of the in vitro interaction between the organism and
the drug.
Present techniques of microbial sensitivity testing generally require overnight incubation
after primary isolation of the infecting organism. This requires a minimum of 48 hours after
the specimen is received in the laboratory. The methods most widely used are agar diffusion
(Kirby-Bauer), broth dilution, and agar dilution (Ericsson and Sherris, 1971; Bauer et al.,
1966; Anderson, 1970; Balows, 1974). Only the agar diffusion technique is reasonably well
standardized and is widely used in clinical microbiology laboratories.
It is clear that the availability of a rapid method of testing bacterial susceptibility would
permit prompt selection of the most effective agent and therefore avoid the inclusion of in-
appropriate, unnecessary-and often toxic—agents in the initial therapeutic regimen.
Although several rapid methods have been described in the past few years (Sellers, et al., 1969;
Isenberg et al., 1971;McKie et al., 1973;Thornsberry et al., 1973; McGowan et al., 1973;
Binford et al., 1973; DeBlanc et al., 1972; Deland, 1972; Boyle et al., 1973; Barry et al.,
1973), all have shortcomings. The measurement of ATP lends itself as an index of bacterial
growth because it can be used for screening specimens for a subsequent susceptibility testing;
it can be made specific for bacterial ATP; with careful standardization of reagents, it is precise,
reproducible, and compatible with automation pand an individual specimen can be assayed for
its ATP content in less than 30 minutes.
Conventional susceptibility testing involving overnight incubation reflects the final result of
a dynamic and complex interaction between the antimicrobial agent and the microorganism.
All currently described methods attempting to rapidly quantitate drug effect will have a
variety of problems in common, which arise from the particular characteristics of the bacte-
rium measured, the mode of action of the antimicrobial agent, and the mechanism of resis-
tance to the antimicrobial agent.
These phenomena are discussed in this document. As Dr. John C. Sherris has cautioned,
"One problem will be to relate (the results of rapid, automated procedures) to those of more
orthodox mean inhibitory concentrations (MIC) methods because of the varying early effects
of sub-MIC concentrations of different chemotherapeutics on different organisms. This poses
the questions of whether such methods can be programmed to give comparable results to
those of an overnight MIC and, perhaps more importantly, of the clinical significance of early
microbial responses to chemotherapeutics as compared with overnight results. It is certainly
possible that the results of an automated procedure may become the future standard against
which other methods are judged" (Balows, 1974).
SECTION 1
PRELIMINARY PROTOCOL, MARCH 1973:
APPLICATION OF LUCIFERASE ASSAY
FOR ATP TO ANTIMICROBIAL DRUG
SENSITIVITY TESTING
INTRODUCTION
The purpose of the preliminary series of experiments is to establish that the inhibition (re-
duction) of bacterial ATP by antimicrobial agents is a valid measurement of drug effect.
The initial protocol will be divided into four parts.
Part 1: Determination of Mean inhibitory Concentrations (MIC)
At present, the MIC is the standard technique by which drug effect versus a specific mi-
croorganism is quantitated. Therefore, it is necessary to determine the MIC of several anti-
microbial agents (penicillin G, ampicillin, tetracycline, sulfisoxazole, gentamicin, and ceph-
alothin) widely used to treat urinary tract infections on representative bacterial species
commonly involved in urinary tract infections. The representative bacterial species are
Escherichia Co//, Klebsiella, Enterobacter, Proteus mirabilis, Pseudomonas aeruginosa,
Staphylococcusi aureus, and Streptococcus faecalis.
Part 2: Effects of Antibiotics on the Amount of ATP per Viable Cell
The effect of the MIC and 2 Iog2 above and below this concentration of the particular anti-
biotic on the log phase growth rate (as measured by the viable colony count) and the bacte-
rial ATP concentration! are measured. This is expected to yield some fixed measurable per-
centage end-point which will correlate well with the MIC. A standard initial concentration
of ~106 organisms/ml will be used.
<
The purpose of starting with an evaluation of the MIC's for the organisms of interest is to
be able to compare results from the ATP assay with those from the technique that is used
as a standard method for evaluating susceptibilities, providing a data base for further work
with urine specimens. It will evaluate the relationship between the viable plate count and
determination of ATP content per bacterium growing in the presence of antibiotics. This
will indicate if it is necessary to measure total count as a function of ATP and viable count
to determine if there is a change in ATP per bacterium caused by the antibiotics.
Part 3: Effect of Inoculum Size on Antibiotic Activity
Since there is considerable range of bacterial concentration hi infected urine specimens, the
effect of varying initial bacterial concentrations (104 ,106, and 108/ml) is studied using the
MIC concentration of the drug.
Part 4: Effect of Urine on Bacterial Growth Rates, ATP, and Drug Activity
Since the objective is to be able to apply the technique directly to infected urine specimens
inoculated into broth, the effect of urine per se on the procedures evaluated in Parts 2 and
3 is studied. Pooled, filtered urine is used for these studies.
PROCEDURES
Parti: MIC Determinations
1 . The representative bacterial species (preferrably American Type Culture Collection
(ATCC) organisms) selected are grown in trypticase soy broth (TSB) at 37°C over-
night.
2. Serial dilutions of the appropriate antibiotic are made in TSB (256, 1 28, 64, 32,
16, 8, 4, 2, 1 , 0.5, 0.25, and 0.125
3. The initial concentration of the organism is ~1 07 (add 0.02 ml of overnight broth
culture to 2 ml of broth containing antibiotic).
4. The tubes are incubated at 37°C for 18 hours, and the least concentration of
antibiotic inhibiting visible growth of the organism will be the MIC.
5 . Control organism of known MIC is run simultaneously .
Part 2: Growth Curves
1 . An overnight broth culture of the test organism is diluted in 37°C TSB to give a
concentration of ~106 organism/ml.
2. This is preincubated in a shaking water bath for 60 to 90 minutes to reach log
phase.
3. To 9^nl aliquots of this broth culture is added 1 .0 ml of the concentrated anti-
biotic solution to yield the required final concentration of antibiotic. The con-
centration evaluated will be the MIC concentration and 2 Iog2 above and below
this concentration. An antibiotic-free control is run simultaneously.
4. Viable colony counts are determined at 0, 2, 4, 6, and 24 hours using the replicate
plate Miles-Misra counting method.
5. The noncentrifuged no-malic acid procedure (Chappelle et al., 1975) for bacterial
ATP will be run on all the aliquots: organisms in broth, with and without the
various antibiotics at different concentrations, at the various time periods, includ-
ing 0 time, a broth blank with each antibiotic, and a broth blank control and a
standard ATP in each broth, with and without antibiotics.
As experience is gained in working with the blanks and antibiotics, some of them may be
eliminated.
6. GSFC has optimized a procedure for use in these studies to determine the ATP
levels in the growing bacteria (Chappelle et al., 1975). This will involve use of
a nonconcentrating procedure using Triton X-100 (TX-100), apyrase, calcium,
and the optimal concentration of HNO3. The use of malic acid buffer to remove
residual ATP would introduce the complication of reducing the intrabacterial
ATP. Since in pure species work, the amount of extrabacterial bound ATP is ex-
pected to be small, there should be no need to use the malic acid. The noncentri-
fuged procedure without malic-arsenate for luciferase assay of bacteria follows:
a. Prepare a 0.5-ml sample: broth culture of bacteria, etc.
b. Add 0.1 ml of Apy-Ca-Tx (10 mg Apyrase/ml 0.03 M Cad2 -0.6 percent
TX-100); wait 15 minutes; vortex well.
c. Add 0.1 ml 1.5 N HNO3; wait 5 minutes; vortex well.
d. Add 4.3 ml H2O; mix well.
e. Assay: Inject 0.1 ml of the above sample into 0.1 ml of DuPont luciferase
reconstituted with 1.5 ml of 0.1 M TRIS (hydroxymethyl) aminomethane,
0.01 MMgSO4,ph8.0.
Recovery: Add 0.05 ml of 10 or 1 mg ATP/ml, depending on desired ac-
curacy of recovery, to the sample after the initial assay, and again inject for
an assay of this standard.
Part 3: Inoculum Size
The previous experiment is repeated using a control and three different initial bacterial con-
centrations at a fixed concentration of drug (MIC). The purpose of this is to evaluate the
differences in inhibition of ATP concentration at varying inoculum sizes which are represen-
tative of the range found in infected urines (104, 106, and 108 organisms/ml).
Part 4: Effect of Urine
1. Pure cultures of organisms in pooled, filtered urine will be prepared at the various
expected concentrations (104 ,106, and 108 organisms/ml).
2. These cultures will be added to broth in various ratios to determine optimal con-
ditions for rapid bacterial multiplication.
3. The effect of the presence of urine at the optimal growth ratios on the ATP assay
will be determined.
SECTION 2
INTERIM PROGRESS REPORT, JULY 1973:
INITIAL PHASES OF THE APPLICATION-MEAN
INHIBITORY CONCENTRATIONS (Mic)
INTRODUCTION
The initial phases of the preliminary protocol were completed in July 1973. The effect of
the MIC, 0.25 MIC, and four times the MIC of gentamicin and tetracycline were measured
on the eight microbial species selected for'evaluation.
Summary of Results
There is a readily-measured, dose-related effect of gentamicin and tetracycline on both the
viable colony counts and bacterial adenosine triphosphate (ATP) in the first 2 to 3 hours of
log phase growth ((figures 2-1 through 2-4 and tables 2-1 through 2-4). The mean doubling
time of the control culture was 30 minutes. The. antibiotics evaluated interfere with the
ability of the bacterium to maintain its intracellular ATP concentration. The magnitude of
the drug effect on ATP is less pronounced than its effect on the ability of the organism to
multiply.
120 180
TIME (minutes)
Figure 2-1. Change in bacterial ATP with time when
bacteria are grown in the presence of gentamicin.
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Figure 2-4. Change in colony counts with time when bacteria are
grown in the presence of tetracycline.
With gentamirin, the effect of the MIC on viable colony counts was predictably different
from the degree of inhibition due to 0.25 MIC. The inhibition of bacterial ATP at the MIC
was such that blank level readings were generally obtained within 2 hours.
With tetracycline, the degree of inhibition of bacterial ATP was never great enough to ap-
proach blank levels nor was the broth ever sterilized. This clearly reflects the differing mode
of action of these two antimicrobial drugs. (That is, gentamicin is bactericidal; tetracycline
is bacteriostatic.)
The degree of inhibition was analyzed by measuring simple differences (that is, 0.5 or 1 log)
between the control and the inhibited curves and by calculating the ratios between the slope
of the inhibited curve and the control curve after 2 hours of log phase growth •
where X2 = assay of inhibited curve after 2 hours
AQ =iassay of control at 0 hour
A2 = assay of control at 2 hours
It was hoped that such calculations (see tables 2-1 through 2-4) would yield some fixed mea-
surable index of inhibition that would correlate well with the tube dilution MIC. No such
predictable index of inhibition could be determined by which we could state that achieving
that end point meant that the MIC had been reached or exceeded.
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CONCLUSION
No fixed measurable index of inhibition could be determined which correlated well with the
tube dilution MIC. This is not surprising because any attempt to correlate the effect of anti-
microbial agents on the metabolic events in the bacterium in the first few hours of log phase
growth with the ability of the drug to inhibit visible (that is, > 107 bacteria/ml) growth at
18 to 24 hours is likely to be futile.
ALTERNATIVE APPROACHES TO THE PROBLEM
One approach would be to utilize some predetermined index of inhibition and compare the
concentration of the drug required to achieve this effect with the tube dilution MIC. This
approach has been used to validate the radiometric method of measuring antibiotic effect on
bacterial growth by DeBlanc et al., 1972. Their analysis resulted in a complex table of dilu-
tion factors that varied from antibiotic to antibiotic versus the same microorganism. Their
results therefore are frankly unconvincing.
Another approach would be to utilize some predetermined index of inhibition and attempt
to validate it as a more accurate and clinically more relevant index of antimicrobial drug
sensitivity testing than the MIC. Considering the degree to which the MIC method and its
derivatives (namely the Kirby-Baueriagar-diffusion\technique) are entrenched in the medical
community and literature, this would appear to be a gargantuan task beyond the present
scope of the study.
A third approach might be the development of a statistical-mathematical model on which we
can analyze our present data to achieve the desired end. This would require professional
consultation.
The most expedient approach, however, would be to model our validation on the method
described by Isenberg et al. (1971). This involves correlating the results of the inhibition of
bacterial ATP with the broad categories of "sensitive," "resistant," and "intermediate" which
are yielded by the Kirby-Bauer technique.
Although rigorous evaluation of the Kirby-Bauer single' disc diffusion method is usually per-
formed by plotting regression graphs comparing agar dilution MIC's and ,disc diffusion zone
diameters (Matsen et al., 1970; Ericsson and Sherris, 1971), nevertheless, the breakpoints
can be determined without necessarily demonstrating a direct linear regression curve. In fact,
often there is a distinctly bimodal distribution of points along these regression curves and
certainly as practiced, the zone diameters cannot be used to predict the precise MIC.
This proposal has been examined in a preliminary way by measuring the index of inhibition
(slope-ratio method) of tetracycline on five bacterial species. The concentrations of tetra-
cycline used were those atjhe upper (16 jug/ml) and lower (4 ng/ml) limits qfbreakpoint
MlCs^see table 2-5). These) results were then compared with the Kirby-Bauer categories.
In each instance, at 4 ng/ml of tetracycline, a sensitive organism yielded a negative index of
inhibition and a resistant microorganism resulted in a positive index. This resolution was
16
clearly evident after only 1 hour of log phase growth. At 16 pig/ml of tetracycline, the re-
sistant \pro tens (yielded a negative index at 1 hour, but this was positive again at 2 hours.
These encouraging results will cause adoption of this mode of evaluation. This will entail
carrying out the Kirby-Bauer agar diffusion techniques rigorously on all isolates.
Table 2-5
Zone-size Interpretive Standards and Approximate MIC
Breakpoints for Disc Diffusion Testing
Antimicrobial
agent
Penicillin G
Ampicillln
Staphylococci
Enterobacteriaceae
& enterococci
Other organisms
Methicillln
Nafcillin or
Oxacillln
Vancomycin
Cephalothtn
Cephaloridine
CarbenlciUin
Pesudomonas sp.
Proteus & £ colt
Polymyxln B }
Chloramphenicol
Tetracycline
Erythromycin
Lmcomycin
Clindamycin
Kanamycin
Neomycin
Streptomycin
Gentamicin
Sulfonamldes § II
Nltrofurantoinll
Nalidixlc Acid
Disc
potency
10 U
(6 3 tig)
lOng
5pi
lug
SOhig
SOfig
30ng
SOhig
300 U
(30|ig)
SOhig
30(ig
15Kg
2h"g
2|Jg
SOhig
30ng
10*ig
lOhig
SOOhig
SOOMg
30ng
Inhibitory zone diameter (to nearest mm)
Resistant
20 or less
11 or less
11 or less
9 or less
10 or less
9 or less
14 or less
11 or less
12 or less
17 or less
10 or less
12 or less
14 or less
13 or less
9 or less
11 or less
13 or less
12 or less
11 or less
12 or less
12 or less
14 or less
13 or less
Intermediate
21-28
12-13
12-21
10-13
11-12
10-11
15-17
12-15
13-14
18-22
11-14
13-17
15-18
14-17
10-14
12-15
14-17
13-16
12-14
13-14
13-16
15-18
14-18
Susceptible
29 or more
14 or more
22 or more
14 or more
13 or more
12 or more
18 or more
16 or more
15 or more
23 or more
15 or more
18 or more
19 or more
18 or more
IS or more
16 or more
18 or more
17 or more
15 or more
15 or more
17 or more
19 or more
19 or more
Approx. MIC breakpoint
Resistant
Pen ase*
z 32 jig/ml
> 32 ^ig/ml
2 32 jig/ml
2 40 Hg/ml
>250 ng/ml
2 32 fig/ml
m<
2 25 ng/m
2 12 5hig/m
2 8 |ig/m
> 8 (ig/m
a 8 Mg/m
2 25 |ig/ml
2 15 Mg/ml
> 12.5ng/ml
2 35 mg%l
2 100 Mg/ml
2 12.5Mg/ml
Susceptible
< 0 lMg/ml
<5-15 (ig/mlt
< 1 Sue/ml
< 2.5(ig/ml
s 0. 6(ig/ml
< 5 Mg/ml
5 10 ng/ml
s 10 fig/ml
< 125 (ig/ml
£ 16 ng/ml
an < 12.5 U/ml
< 12 5ng/ml
< 4 (ig/ml
z 2 Mg/m
< 2 Mg/m
< 2 Mg/m
< 6 Mg/m
£ 10 Mg/m
i 6 Mg/ml
< 6 Mg/ml
< 10 mg%ll
s 25 Mg/ml
s 12.5Mg/ml
*Penicillinase—producing staphylococcl.
TMIC dependent upon dilution method used.
JPolymyxin B diffused poorly in agar and the accuracy of the diffusion mehtod is less than with other antlmlcroblcs.
Resistance is always significant, but when treatment of systemic Infections due to susceptible strains Is considered, it
Is wise to confirm the results of a diffusion test with a dilution method
§300Mg or 250Mg sulfonamlde disc can be used with the same standards of zone Interpretation (MIC values are
for sulfamethizole).
llUrinary tract Infections only.
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TECHNICAL MODIFICATIONS
During the initial phase of study, several procedural.changes have occurred. Simultaneous
viable colony \counts will no longer be performed because they are very time-consuming and do
not appear to yield substantive data relevant to the present purpose. The frozen glass bead
method of storage of stock cultures has proven somewhat disappointing, as several of the
organisms do not yield heavy broth cultures after overnight incubation. Agarslants will be
used. In order to increase the yield of work, both the DuPont Luminescence 760 Biometer
and the Aminco Chem-Glow photometer',will be used to assay ATP (Nibley and Thomas,
1976). At the present initial inoculum size (~106 viable organisms/ml), a concentrating
procedure (that is, centrifugation) is not necessary.
The source of the apparent discrepancy between the viable colony counts and the conversion
of bacterial ATP to numbers of bacteria has not yet been determined. This one log difference
is not due to error in preparing ATP standards, nor is it related to differences in instrumen-
/
tation. It most likely reflects procedural changes in the method of assay of bacterial ATP,
possibly the omission of the malic-arsenate buffer step.
18
SECTION 3
INTERIM PROGRESS REPORT, AUGUST 1973:
CORRELATION WITH STANDARD KIRBY-BAUER METHODOLOGY
INTRODUCTION
Because preliminary results of the protocol precluded correlation with tube-dilution MIC's,
as described in the previous section, the correlation of the results of the inhibition of bacte-
rial ATP with the broad categories of "sensitive," "resistant," and "intermediate" designated
by the Kirby-Bauer agar diffusion technique was attempted.
METHODS
The Kirby-Bauer agar diffusion technique was carried out exactly according to the standards
recommended by the National Committee for Clinical Laboratory Standards in August 1972.
Inhibition of bacterial ATP was generally measured at two antibiotic concentrations approxi-
mating the MIC breakpoints. This will help to determine the single antibiotic concentration
which results in the best discrimination. Samples were assayed at 0 hour (that is, after a 1-
hour preincubation period) and after 1 and 2 hours of log phase growth. The degree of inhi-
bition was quantitated by the slope-ratio method. The tentative interpretation of the Index
of Inhibition is as follows:
ATP INDEX INTERPRETATION
> + 0.25 Resistant
0.15 to 0.24 Intermediate
< 0.15 Sensitive
RESULTS AND DISCUSSION
(3-Lactam Antibiotics •
When a |3-lactam antibiotic is added to a sensitive gram-negative bacterium in the logarithmic
phase of growth, the bacterium undergoes a series of morphologic changes from filamentous
'forms to bulbous or "bow-tie" forms to spheroplasts before finally undergoing osmotic lysis
(Greenwood and O'Grady, 1973). These changes are related to drug-induced alterations in
the cell-wall structure and may be dependent on the relative inhibitory effect of /3-lactam
antibiotics on two different enzymes: an endopeptidase concerned with cell division and a
glycosidase concerned with cell growth (Hartmann et al., 1972). The rates at which these
changes occur are dependent on the concentration of the drug, the type and rate of pro-
duction of 0-lactamase by the bacterium, and the stability of the drug to penicillinase. Also,
the time to lysis is dependent on the osmolality1 of the medium (being more rapid at lower
19
osmolalities) and the osmotic susceptibility of the species with damaged cell walls (E. Coll
being more susceptible than P. mirabilis). Continuous turbidometric recordings of these
events show increasing opacification of the culture (despite lack of cell division) for varying
lengths of time after the addition of the drug until lysis occurs (Greenwood and O'Grady,
1973).
Conventional susceptibility testing requiring overnight incubation merely reflects the final \
result of this complex series of responses. When bacterial ATP is used as a measure of |3-
lactam antibiotic effect on log phase cultures, it is apparent that the drop in bacterial ATP
(indicating sensitivity) coincides with the time to achieve lysis. This time to achieve lysis
has varied from less than 1 hour to greater than 6 hours. Accordingly, this delay restricts
the rapidity by which sensitivity can be determined by the ATP technique. As well, the
addition of Triton X-100 in the assay procedure will enhance osmotic lysis of these cell-wall-
deficient bacteria.
Penicillin G
Bacterial susceptibility to penicillin G (see tables 3-1, 3-2, 3-3, and 3-4) is a rather complex
problem. Strains of S. aureus need special consideration because those with MIC's of over
0.1 jig/ml are almost invariably penicillinase producers and by definition must be reported
as resistant. Both a penicillin-sensitive S. aureus (ATCC 25923) and a penicillin-resistant
S. aureus\(S-l8T) were evaluated at 0.15 Mg/ml and discrimination was possible at 2 hours
(table 3-4).
Clinical experience has shown thatenterococci, P mirabilis, and some strains of E. co/rwith
MIC's up to 128 jug/ml respond to penicillin—especially in unnary tract infections. Accord-
ingly, the sensitivity data at 128 Mg/ml in table 3-1 must be interpreted in relation to the
MIC's. Comparison with the Kirby-Bauer technique is not valid.
In view of these factors, it is difficult to choose a single concentration of penicillin G, be-
cause choosing the higher concentrations applicable to urinary tract infections might lead
to incorrect interpretation of S. aureus sensitivity.
The time to lysis was studied with E. coli and penicillin G (figure 3-1) and shown to be about
2 hours. The effect of Triton X-100 was measured and shown to be negligible on the con-
trol culture, but there is a population of penicillin G-induced cell-wall-deficient organisms
which are susceptible to Triton X-100 lysis. This latter effect did not alter the interpretation
of the sensitivity test.
Ampicillin
The correlation with the Kirby-Bauer.technique (see tables 3-5 and 3-6) was good in the
8 to 16 ng/ml range except for P. mirabilis, which was consistently falsely-resistant. The
explanation for this lies in the fact that the time to lysis with this particular combination
is 3 hours (figure 3-2).
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Figure 3-1. Time to lysis of E. coll grown in the presence of penicillin
(128 jug/ml) with and without TX.
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Figure 3-2. Time to lysis: jP. mirabilis grown in the presence of ampicillin.
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Nafcillin
The use of nafcillin (see tables 3-4 and 3-7) is limited to penicillinase-producing S. aureus,
so the evaluation of this drug was restricted to a penicillin-sensitive (ATCC 25923) and a
penicillin-resistant (S-187) strain of S. aureus. Only one antibiotic concentration was used
because higher values imply resistance. The ability of the ATP technique to discriminate
between these two strains was complete at 2 hours.
Carbenicillin
Although carbenicillin (see tables 3-8, 3-9, and 3-10) is of limited usefulness, we included it
in our study because of the recent availability of an oral form, Indanyl Carbenicillin, recom-
mended for urinary tract infections. Disc-sensitivity data are available only for Pseudomonas,
E. coli, and Proteus, so comparison is restricted to these species (Schoenknecht, 1973). The
MIC breakpoints also differ between these species adding additional complexity, although
bacteria inhibited by concentrations achieved in the urine should be considered sensitive to
this agent.
The correlation is complete with E. coli and Proteus at 2 hours, but the Pseudomonas is
falsely-resistant. A more detailed study of this (figure 3-3) demonstrated a markedly pro-
longed time to lysis of between 6 and 24 hours, making "rapid" sensitivity testing by this
method impossible.
Cephalothin
The correlation with cephalothin (table 3-11) is excellent at the higher concentration (32
jug/ml). The apparent discrepancy with the enterococcus is not bothersome since the MIC
of 32 jug/ml is borderline and does not correlate well with the disc-sensitivity method. It is
worth emphasizing that the ATP index may in certain instances correlate better with the
MIC than the disc-sensitivity result and that these should not necessarily be considered as
discordant results.
Tetracycline
At 4 Aig/ml, the correlation with tetracycline (see table 3-12) is 100 percent except for
Pseudomonas where the index falls into the intermediate range at 2 hours. We have not
studied this in more detail. Both the Proteus and Pseudomonas are falsely-sensitive at 16
jig/ml. Therefore the final concentration chosen should be ~ 6 jug/ml.
Erythromycin
Although erythromycin (tables 3-13 and 3-14) generally has limited usefulness in the treat-
ment of urinary tract infections due to its limited antibacterial spectrum, there are studies
(Zinner et al., 1971) to indicate that alkalinization of the urine increases this drug's activity
and antibacterial spectrum to include most gram-negative bacilli. The correlation between
the Kirby-Bauer and the ATP index is 100 percent at 1 and 2 hours.
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CONTROL
CONTROL
TIME (hrs)
Figure 3-3. Time to lysis Pseudomonas Aeruglnosa grown in the presence of carbenicillin
(128 /Ltg/ml) with and without TX.
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Clindamycin
The distribution of sensitivities to clindamycin (tables 3-15 and 3-16) is clearly bimodal and
susceptibility discrimination is relatively clear-cut The results with an enterococcusare
 (
interesting in that although this organism was considered resistant to clindamycin by the
agar diffusion technique, the MIC value of 8 /ng/ml suggests a more intermediate suscepti-
bility that corresponds better with the ATP index. In this instance the apparent discrepancy
is not serious.
Gentamicin
There is 100 percent correlation at both antibiotic concentrations of gentamicin (see table
3-17).
Sulfisoxazole
Preliminary results with sulfisoxazole (see tables 3-18, 3-19, 3-20 and 3-21) suggest several
difficult problems.
Because bacteria undergo several generations until the effect of the sulfonamide become
apparent (see table 3-21 and figure 3-4), very low inocula (~5 X 102 to 5 X 103 organisms/
ml) must be used. There does not appear to be any consistent sulfonamide effect produced
after 3 hours of log phase growth using an inoculum of ~5 X 104 organisms/ml (see table
3-19, 3-20 and figure 3-5), making "rapid" sensitivity testing to this agent impossible. There
will be further study of the kinetics of sulfonamide effect on bacterial cultures but it is
doubtful that the methods and criteria used for antibiotics can be applied to sulfonamides.
SUMMARY
By careful selection of antibiotic concentration and duration of growth in the presence of
the drug, we can exceed 90 percent correlation with the Kirby-Bauer agar diffusion tech-
nique.
The exceptions to the above generalization can be explained either by prolonged time to
lysis with some 0-lactam antibiotics or by prolonged delay in antibacterial effect as exempli-
fied by the sulfonamides.
At times, the ATP index correlates better with the tube-dilution MIC than the Kirby-Bauer
technique and apparent discrepancies in these instances are not serious.
The tentative criteria that we have adopted for the interpretation of the ATP index of
inhibition may-be subject to some revision once additional experience has been gained with
this technique.
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Figure 3-4. Change in bacterial ATP and colony counts with time when
o
~ 10 E. coll are grown in the presence of sulfisoxazole.
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Figure 3-5. Change in bacterial ATP and colony counts with time when
~ 105 £. co// are grown in the presence of sulfisoxazole.
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SECTION 4
INTERIM PROGRESS REPORT, OCTOBER 1973:
EFFECT OF ANTIMICROBIAL AGENTS ON BACTERIAL ATP
INTRODUCTION
The purpose of the preliminary experiments performed was to establish that the reduction
of bacterial ATP content by antimicrobial agents is a valid measure of drug effect. This
effort included the work necessary to optimize the luciferase assay for ATP for application
to pure cultures in broth, establish the optimum duration of premcubation and incubation,
determine for each antimicrobial agent the concentration which results in the best discrim-
ination between sensitive and resistant strains, and to develop an index of inhibition to
quantitate the drug effect on bacterial ATP.
The results of this aspect of the work are summarized in table 4-1, which compares the broth
dilution MIC and agar disc-diffusion method with the ATP index.
The ATP index is expressed as the mean of duplicate determinations except in the one
instance (P. mirabilis versus penicillin G at 8 jug/ml) where these were markedly different.
There is a 94 percent agreement in the results of the three methods. The discordant results
will be analyzed in detail in the discussion of problems below. An ATP index of inhibition
has been developed that, in a preliminary evaluation, has a 94-percent'correlation with' stan-
dard agar disc-diffusion sensitivity tests after only 3 hours.
PROJECTED STUDIES
The size of the bacterial inoculum is a cntical variable in determining the results of standard
microbial susceptibility tests. It is possible that this may not be as critical a determinant in
rapid sensitivity tests. To evaluate this effect, the basic procedure is repeated using three
bacterial inoculum sizes: 5 X 104,5 X 106 ,and5 X 107 colony-forming units/ml. For the
lowest inoculum size (5 X 104), an alternative ATP assay, the short centrifugation procedure
(Chappelle\et al., 1975), has been developed to give the increased sensitivity required.
SOME PROBLEMS WITH RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING WITH
SPECIAL REFERENCE TO THE ATP INDEX OF INHIBITION
Conventional susceptibility testing requiring overnight incubation reflects the final result of
a dynamic and complex interaction between the antimicrobial agent and the microorganism.
All currently described methods attempting to rapidly quantitate drug effect, whether by
hemoglobin reduction (Sellers et al., 1969), sensitive turbidometnc techniques, microcalori-
metry (Binford et al., 1973), radiometric means (DeBlanc et al., 1972; DeLand, 1972; Isen-
berg et al., 1971; McKie et al., 1973;Thornsberry et al., 1973; McGowan et al., 1973), early
zone measurement of the standard agar disc-diffusion technique (Boyle et al., 1973; Barry
et al., 1973), or as we have done, measuring bacterial ATP content, will have many similar
problems.
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Four major factors will affect all of these tests, and they are as follows: the particular prop-
erty of the bacterium measured, the mode of action of the "antimicrobial agent, the mecha-
nism of resistance to the antimicrobial agent, and the fact that a bacterial inoculum in the
order of 106 colony-forming units/ml may behave in a heterogenous manner to an antimi-
crobial agent.
DETERMINATION OF THE PROPERTY OF THE BACTERIUM MEASURED BY ATP
The majority of the ATP of aerobic bacteria is supplied by oxidative phosphorylation, which
in turn is coupled to bacterial respiratory chains. Thus, the bacterial ATP content is related
to the functional integrity of these two processes and it declines if bacteria are exposed to
uncouplers or are made anaerobic (Harold, 1972). Although none of the commonly used
antimicrobial agents acts directly on these processes, it is evident that indirectly they may
have profound consequences on bacterial ATP.
In addition to these general principles, several notable factors influence the bacterial ATP
content. These are: the microbial species; the growth cycle (rapidly multiplying log phase
cultures contain more ATP/bacterium than lag phase or early stationary phase cultures); the
composition and redox state of the growth medium; and the method of extraction of ATP
and its assay.
Although attempts have been made to correlate bacterial ATP with absolute numbers of
microorganisms or colony-forming units (using a conversion factor of 2.75 X 10"1 fg ATP/
bacterium), the above data suggest that this supposition is invalid. Changes in bacterial ATP
more closely parallel the turbidity (or mass) of the culture and since 50 percent of the dry
weight of E. coli is protein, it may be inferred that bacterial ATP closely parallels the bac-
terial protein content.
EFFECT OF MODE OF ACTION OF ANTIMICROBIAL DRUGS ON RAPID SENSITIVITY
TESTING
One of the shortcomings of agar disc-diffusion sensitivity testing is that it gives no information
about the mode of action of the particular agent. Our experience to date clearly demon-
strates that the early changes in bacterial ATP content are dependent upon the mechanism
of action of the drug.
Agents that Alter Protein Synthesis
In general terms, these agents exert their antibacterial effect by acting on bacterial ribosomes.
We have found that gentamicin, tetracycline, chloramphenicol, erythromycin, and clindamycin
rapidly inhibit bacterial ATP synthesis in susceptible species and that sensitivity or resistance
to the agent can be determined within 1 hour. A "bacteriocidal" agent, such as gentamicin,
produces a rapid fall in bacterial ATP, suggesting a profound effect on the functional integrity
of the bacterium. A bacteriostatic agent such as tetracycline inhibits further ATP synthesis
without any actual significant drop in bacterial ATP content (figure 4-1).
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Cell Wall-Active (0-Lactam) Antibiotics
When a j3-lactam antibiotic is added to a sensitive gram-negative bacterium in the logarithmic
phase of growth, the bacterium undergoes a series of morphological changes from filamentous
to bulbous or "bow tie" forms to spheroplasts before finally undergoing osmotic lysis (Green-
wood and O'Grady, 1973). These changes are related to drug-induced alterations in the cell
wall structure and may be dependent on the relative inhibitory effect of /Hactam antibiotics
on two different enzymes, an endopeptidase concerned with cell division and a glycosidase
concerned with cell growth (Hartmann et al., 1972). The rate at which these changes occur
is dependent on the concentration of the drug, the type and rate of production of 0-lactamase
by the bacterium, and the stability of the drug to j3-lactamase. In addition, the time to lysis
is dependent on the osmolality of the medium (being more rapid at lower osmolatities) and
the osmotic susceptibility of the species with damaged cell walls (E. coli being more suscep-
tible than P. mirabilis). Continuous turbidometnc recordings of these counts show increasing
opacification of the broth culture (despite lack of cell division) for varying'lengths of time
after the addition of the drug until lysis occurs (Greenwood and O'Grady, 1973). Bacterial
protein synthesis is not inhibited by this class of drugs.
When bacterial ATP content is used as a measure of j3-lactam antibiotic effect on lag-phase
cultures, the drop in ATP (indicating sensitivity) coincides with the time to achieve lysis.
The time to achieve lysis has varied from less than 1 hour to greater than 6 hours. The pro-
longed time to achieve lysis seen with penicillin G and ampicillin against P. mirabilis (figure
4-2) and carbenicilhn against P. aeruginosa (> 6 hours) limits the rapidity by which sensitivity
can be determined by techniques that measure bacterial mass, protein synthesis, ATP, or
other metabolic parameters apart from cell-wall synthesis.
In addition, there may be some delay in the expression of the organism's ability to produce
sufficient quantities of a drug-inactivating enzyme (such as j3-lactamase), the genetic capability
of which implies resistance. This problem is particularly pertinent to penicillinase-producing
S. aureus, which frequently appears sensitive to penicillin after only a few hours of growth
(DeBlanc et al., 1972).
Sulfonamides
This class of chemotherapeutic agents act as competitive inhibitors of p-amino benzoic acid
in the biosynthetic reaction to form dihydrofolate in bacteria. In vitro sensitivity testing to
sulfonamides has always presented special difficulties due to the presence of substances in
many microbiological media that inhibit the antibacterial action of sulfonamides (although
they can be neutralized by the addition of lysed horse blood); and the necessity to use a very
small inoculum of organisms, since bacteria may undergo many generations (Garrett and
Wright, 1967), before any drug effect becomes apparent.
The latter point effectively precludes "rapid" measurement of drug effect; as would be
expected, the ATP index consistently gives false resistant results (figure 4-3).
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Nalidixic Acid
In our preliminary work, the ATP index consistently gave false resistant results (figure 4-4).
This is not surprising because'analysis of the mode of action of this antimicrobial agent has
shown that it selectively inhibits bacterial DNA synthesis without significantly altering RNA,
protein, or lipid synthesis (Goss et al., 1964). Nalidixic acid also has little or no effect on
respiration with glucose as a substance. Thus, turbidometric and radiometric methods are
also likely to show false resistance to this agent.
HETEROGENEITY OF THE BACTERIAL INOCULUM
There may be a substantial portion of a bacterial inoculum, on the order of 106 colony-
forming units/ml, that are immediately susceptible to the effects of the antibiotic, while
the residual population is still able to recover to indicate resistance by the usual methods
requiring overnight incubation.
This phenomenon is also illustrated in uncommon instances where, despite an apparent zone
of inhibition in the susceptible range by agar diffusion, several colonies are seen within the
zone. Provided punty of the strain can be confirmed, this must be interpreted as resistance
(Bauer et al., 1966). Rapid susceptibility methods are likely to report them as falsely sensi-
tive, as in the case of Enterobacter versus colistin.
A variant of this effect is illustrated by Enterococcus versus clindamycin, where as little as
0.063 of the MIC markedly prolongs the lag phase resulting in false sensitive interpretation
(figure 4-5).
SUMMARY
We have attempted to give adequate explanations for the discrepancies that we have found
between the ATP index and agar disc-diffusion techniques. Most, if not all of these, are
shared by other techniques for rapid determination of microbial susceptibility.
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SECTION 5
, INTERIM PROGRESS REPORT, JANUARY 1975:
DIRECT APPLICATION OF ATP ANTIMICROBIAL
SUSCEPTIBILITY TESTING TO URINE SPECIMENS
INTRODUCTION
In July 1974, attention turned to the major objective of applying the luciferase antimicrobial
susceptibility methods directly to urine specimens. The effort included:
• Evaluation of centrifugation to isolate organisms from urine specimens for sub-
sequent susceptibility tests
• Evaluation of the effect of urine (material accompanying the bacteria in the sed-
iment) on the luciferase antimicrobial susceptibility methods
• Preliminary evaluation of the method with clinical urine samples
• Use of an ATP assay (the long centrifugation method) suited for detection of
bacteriurias to establish appropriate inoculum size for susceptibility testing
•
 -
 Addition of kanamycin and streptomycin to antibiotics being evaluated
• Modification of certain technical aspects of methods to increase efficiency and
accuracy
• Evaluation of the modified method, incorporating the last three efforts listed
above, with clinical urine samples, including a detailed analysis of errors.
EVALUATION OF CENTRIFUGATION TO ISOLATE ORGANISMS FROM URINE SPEC-
IMENS FOR SUBSEQUENT SUSCEPTIBILITY TESTING
The susceptibility testing method employing the firefly luciferase ATP assay requires a cer-
tain inoculum size and the presence of organisms in growth media for consistent growth
patterns from sample to sample. These requirements were the initial considerations in apply-
ing the method directly to urine samples. The concept of using the urine itself as growth
media was first considered. Unfortunately, at least two physiochemical parameters of urine
greatly alter growth of pathogens in urines. Others have disclosed the effects of pH and os-
molality on mean generation time of E. coli as shown in figures 5-1 and 5-2.
Perhaps pH could be adjusted, but osmolality would be difficult to adjust for each sample.
Clearly the best approach would be to separate the organisms from the urine. The effects
of pH and osmolality could be eliminated, and the inoculum size could be controlled.
Centrifugation and filtration were considered. Filtration of the volume necessary to achieve
an appropriate inoculum size is difficult. Centrifugation of urine has been shown previously
to give workable recovery of (organisms (unpublished work performed at Goddard Space
Flight Center).
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Figure 5-1. Effect of urinary pH on the growth rate of E. coli.
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Figure 5-2. Effect of variation of urinary pH and osmolality on the growth rate of E. coli.
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Centrifugation was evaluated as a means to isolate organisms from the urine. Experiments
were designed to allow the additional evaluation of the ability to achieve and use an inoculum
size of approximately 1 X 10s organisms/ml which can be measured by the non concentrated
procedure without malic acid for luciferase assay of bacterial ATP (method employed by
Vellendjin pure species work and described on page 8). With a three-fold concentration by
centrifugation, this inoculum size could be achieved from urines with thirty thousand orga-
nisms per ml, the lowest bacterial count considered to represent a significant bacteriuria at the
Microbiology Laboratory at NEMCH.
Experimental Plan
Sterile urine was infected with various reference organisms to give 30,000 organisms/ml.
Forty-five ml of infected urine were centrifuged at 8000 RCF X G for 15 minutes at 4°C.
The supernate was decanted, and the tube allowed to drain in the upright position approxi-
mately 30 seconds. The bacterial pellet was reconstituted in 1 5 ml of TSB to give a final
concentration of 90,000 bacteria/ml. This specimen was then handled exactly as Dr. Vellend
has described for his pure culture work using the nonconcentrated procedure without malic
acid for luciferase assay. After preincubation of the sample at 37°C for 30 minutes, aliquots
of 0.9 ml were placed into each of 14 tubes. Tube A contained 0.1 ml of sterile water and
served as AQ and growth control for all antibiotics except nitrofurantoin. Tube ANjtro con-
tained 0.2 ml of TSB and served as AO and growth control for nitrofurantoin. Tube Bj 12
contained 0.1 ml of an antibiotic solution in sterile water to yield a final concentration shown
in the following list. BNilro contained 0.2 ml of an antibiotic solution in TSB to yield a final
concentration of 50 Mg/ml of nitrofurantoin.
Antimicrobial Agents Used in Preliminary Studies
Drugs Concentration (jug/ml)
Penicillin 8
Ampicillin 8
Nafcillin 0.6
Carbenicillin 1 28
Cephalothin 1 6
Tetracycline 6
Chloramphenicol . . 12.5
Qindamycin 2
Erythromycin 4
Gentamicin 6
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Drugs Concentration (jug/ml)
Colistin 8
Kanamycin 16
Streptomycin 10
Nitrofurantoin 50
From the control tubes A and ANitro, 0.5 ml of the cultures were assayed immediately for
ATP (A0). All tubes were then incubated at 37°C for 2.5 hours. After incubation 0.5-ml
samples were assayed for ATP.
All ATP assays were performed using the following method'
1. Pipette 0.5 ml sample of broth culture into a sterile polypropylene tube (17 X 100
mm).
2. Add 0.1 ml Apy-Ca-TX, vortex well, and wait 5 minutes.
3. Add 0.1 ml of 1.5 N nitric acid to extract bacterial ATP, vortex well, and wait
5 minutes.
4. Add 4.3 ml of sterile deionized water and mix well.
5. Using a disposable tuberculin syringe, inject 0.1 ml of the mixture into the
luciferase reagent (rehydrated in 0.25 M TRIS, 0.01 M MgSO4, at pH 8.0).
6. Measure light response in photometer.
Samples
The urine samples were first-voided specimens from a healthy volunteer. Sterility was es-
tablished by usual culture techniques. Urinalysis revealed specific gravities that ranged from
1.016 to 1.021. A range of pH from 5.0 to 6.0 was determined by BilHabstix® (Ames).
Chemistries by BilHabstix® were negative for blood, bilirubin, ketones, glucose, and protein.
Microscopic examination of sediment revealed only an occasional white blood cell (wbc),
red blood cell (rbc), or crystal.
The reference strains were those previously used to validate the ATP technique. Two ref-
erence strains were provided by the Food and Drug Administration:
(lystaphylococcus aureusATCC 25923 and (2) Escherichia coli ATCC 25922. Other species
used were strains isolated from urine specimens submitted to the diagnostic Microbiology
Laboratory at the NEMCH: Klebsiella aerogenes 07220, Enterobacter cloacae 05248,
Proteus mirabilis 04583,Pseudomonas aeruginosa Q4215,Enterococcus (Streptococcus
fecalis) 04390, and Staphylococcus epidermidis 05995.
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Table 5-1
Comparison of Antibiotic Susceptibility Results by Standard Kirby-Bauer Test
with Results Using ATP Method and Proposed Centrifugation
Procedure to Isolate Bacteria from Urine
Antibiotic Index ATPInterpretation KB
KB
Interpretation Usable
Disagreement
with KB
30,000 S aureus
A0 = 2.86 x 105, A£ 5 = 3 05 x 106
Penicillin
Ample ill in
Nafcillui
CarbemciHin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Eiythromycin
Gentamicin
Cohstin
Nitrofurantoin
-0 03
-0 02
-0 04
-0 03
+0.08
-0.01
-0.01
-0.00
+0 01
-0.01
+0 44
-0 01
S
S
S
S
R
S
S
S
S
S
R
S
32.5
31
19.5
-
32.5
25.5
24
26
28
24
0
18.5
S
S
S
-
S
S
S
S
S
S
R
S
-
(false R)
30, 000 Enterococcus
A0 = 1. 30 x 106, A2 5 = 8. 07 x 107
Penicillin
Ampicillin
Natcillin
Carbemcillin
Cephalothin
Tetracyclme
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistm
Nitrofurantoin
-0 01
-0 01
+0 87
-0 01
+0 19
+0 01
+0 00
+0 01
+0 01
+0.25
+1.07
+0.04
S
S
R
S
R
S
S
S
S
R
R
S
18
22
-
-
14
20
22
0
26
13
0
23
I
S
-
-
R
S
S
R
S
S
R
S
-
-
(false S)
(false R)
30, 000 P mirabihs
A0 = 6 86 x 105, A2 5 = 4 19 x 107
Penicillin
Ampicillin
Nafcillin
CarbemciHin
Cephalothin
Tetracycl me
Chloramphemcol
Clindamycin
Eiythromycin
Gentamicin
Coltstin
Nitrofurantoin
-0 01
-0 01
+0 87
-0 01
+0 00
+0.46
-0.00
+0 89
+0 80
-0 01
+0.56
+0.39
S
S
H
S
S
R
S
R
R
S
H
R
20
26.5
-
30
20
0
28
0
0
22
0
11
I
S
-
S
S
R
S
R
R
S
R
R
-
30,000 £ cull
A0 = 0 33 x 105, A2.5 = 1.13xl07
Penicillin
Ampicillin
Nafcillin
CarbemciHin
Cephalothin
Tetracyclme
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistm
Nitrofurantoin
+0 80
-0 00
+0 78
-0 00
-0 00
+0 01
+0 01
+0 75
+0 75
-0 00
-0 00
-0 01
R
S
R
S
S
S
S
R
S
S
S
S
0
19
-
28
19
20
25.5
0
10.5
22
15.5
23.5
R
S
-
S
S
S
S
R
R
S
S
S
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Table 5-1 (Continued)
Antibiotic Index ATPInterpretation KB
KB
Interpretation Usable
Disagreement
with KB
30, 000 Klebnella pneumonias
A0 = 4.64X 105, A2-5 = 4. 72 x 107
Penicillin
Ampicillm
Nalcillin
Carbeniclllin
Cephalothin
Tetracyclme
Chloramphenicol
Clindamycm
Erythromycin
Gentamicin
Colistin
Nitrofurantoin
+1 33
+1.04
+1.04
+1.10
-0.01
+0 01
+0.01
+1.13
+1 23
-0 01
-0 00
+0 14
R
R
R
R
S
S
S
R
R
S
S
R
0
0
-
-
21
19
29.5
0
11
22
16
13
R
R
-
-
S
S
S
R
R
S
S
R
-
-
30, 000 Enterobacter
A0 = 4.1 x 105, A2-5 = 5.30 x 106
Penicillin
Ampicillin
Natcillin
Carbeniclllin
Cephalothin
Tetracycllne
Chloramphenicol
Clindamycm
Erythromycin
Gentamicin
Colistin
Nitrofurantoin
+1 11
+1 21
+1 22
-0 03
+1.18
+0 01
-0.01
+1.01
+0.83
-0 05
+0 88
+0 03
R
R
R
S
R
S
S
R
R
S
R
S
0
0
-
-
0
19
26
0
0
24
13
22
R
R
-
-
H
S
S
R
R
S
S
S
-
-
(false R)
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Results
Table 5-1 reports the results for six reference strains. The reference organism and light units
obtained for growth controls A0 and A2 s are given initially in each case. The column marked
Index lists the ATP index of inhibition for each antibiotic calculated as follows:
ATP - "o
Index A^ - AO
where A0 = light units for growth control after 0.5 hour preincubation at 37°C; A2 5 = light
units for growth control after 2.5 hours of incubation at 37°C; and B = light units for sample
containing appropriate antibiotic concentration after 2.5 hours of incubation at 37°C.
The column marked ATP Interpretation gives the interpretation of an index according to the
criteria:
Resistant (R) >OD5
Sensitive (S) <OD5
The column marked KB gives zone diameters in millimeters of the Kirby-BaUer agar diffusion
technique for the organism being tested. Technique and interpretation of resulting values
were carried out according to the standards recommended by the National Committee for
Clinical Laboratory Standards in August 1972.
The far right column notes when ATP results disagreed with Kirby-Bauer results. If the
Kirby-Bauer interpretation was sensitive and the ATP interpretation resistant, the ATP result
was labeled as false^esistant. If the Kirby-Bauer interpretation was resistant and the ATP
sensitive, the ATP result was considered false-sensitive.
Discussion
Good correlation between the Kirby-Bauer and ATP techniques was achieved under these
conditions. Of 63 determinations, only 4 disagreements were found, giving a 93.6-percent
correlation.
Two major points were established. First, centrifugation could be used tojisolate organisms
from urine, and the material accompanying the bacteria in the sediment (in this case amor-
phous material, occasional crystals, white blood cells, and red blood cells) did not interfere
with subsequent antibiotic sensitivity testing. Second, an inoculum of approximately 1 X 10s
could be used successfully with the nonconcentrated procedure without malic acid for luci-
ferase assay. Success at an inoculum of 1 X 106 had been established in earlier studies.
Furthermore, this inoculum size could be achieved from urines with 30,000 organisms/ml
by a 3-fold concentration. This indicated that even a minimally significant bacteriuna of
30,000 organisms/ml could be evaluated successfully.
67
EVALUATION OF THE EFFECT OF URINE (MATERIAL ACCOMPANYING THE
BACTERIA IN THE SEDIMENT) ON THE LUCIFERASE ANTIMICROBIAL SUSCEPTI-
BILITY METHODS
The concern prompting this study was that the urinary sediment could contain material that
would interfere with the growth of bacteria, with antibiotic activity, or with the ATP assay
itself. Any one of these influences could hinder the sensitivity testing and reduce correlation
with the Kirby-Bauer technique.
Experimental Plan
To evaluate this problem, sterile urines (no growth on overnight plates) were obtained from
patients with various clinical conditions or metabolic disorders, who were taking a variety of
medications, including antibiotics. The urines were artifically infected with 30,000 organisms/
ml of reference strain E. coli. The procedure was carried out exactly as described above using
the nonconcentrated procedure without malic acid.
Patients had a variety of diagnoses which included pneumonia, serum hepatitis, rectal abscess,
hypothyroidism, inflammatory bowel disease, carcinoma of bladder, lymphoma, endometrial
caricinoma, floppy mitral valve, and abdominal aneurysm. Metabolic disorders included
diabetes mellitus in one case and hypercholesterolemia in another.
Medications included isoniazid, folic acid, pyridoxine, codeine phosphate, prochlorpenazine,
acetaminophen, diszepam, procarbazine, diphenhydramine hydrochloride, flurazepam, hydro-
chlorothiazide, spironoactone, clofibrate, prednisome, methyldopa, indomethacin, and
dioctyl sodium sulfusuccinate.
Six patients were on antibiotics, which included two on cefazolin sodium, two on cephalothin,
one on penicillin, and one on both oxacillin and ampicillin. Urinalysis revealed that specific
gravities ranged from 1.005 to 1.035, and pH ranged from 5.0 to 7.0. Chemistries by Bili-
labstix® revealed that two patients had 1+ protein. Sediment exam revealed amorphous
debris in many cases, rare white blood counts in five cases, rare epithelial cells in three cases,
one case with 5.7 X 103 renal tubular celts, and one case with 2.0 X 104 white blood cells/
ml.
Results
Table 5-2 is a tabulation of the results obtained during this evaluation. The table is similar
in format to table 5-1 and the previous explanation applies.
There was good correlation between the Kirby-Bauer and the ATP method with urines from
patients who were not on antibiotics. Sample numbers 2, 3,4, 8, 9,11, 12,13, and 15 were
from patients who were not taking antibiotics, and there was only one point of disagreement
(erythromycin, false S, sample 9) in 54 determinations representing a 98-percent correlation.
There was poor correlation found with three samples. Samples numbers 7 and 10 had a 50-
percent correlation, and sample number 1 agreed at only one point. In all these cases, the
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Table 5-2
Results of the Evaluation of the Effect of Urine on the
- Luciferase Antimicrobial Susceptibility Methods with
30,000 Escherichia coll per ml
Antibiotic Index ATPInterpretation
Kirby-
Bauer
Kirby-Bauer
Interpretation
Disagreement
with Kirby-Bauer
Sample No 1 A0 = 0 14 x 105, A2 5 = 0 36 « 105
Ampicilhn
Cephalothln
Tetracyclme
Chloramphenlcol
Enythromycin
Gentamicin
+0 18
+ 1.00
+3 59
+7 23
+1 32
+6 63
R
R
R
R
R
R
19
19
20
25 5
10 5
22
S
S
S
S
R
S
false R
false R
false R
false R
false R
Sample No 2 A0 = 2. 13 x lo5, A2 5 = 2.39 « 107
Ampiclllm
Cephalothln
Tetracycline
Chloramphenlcol
Enythromynn
Gentamicin
-0 01
-0 01
+0.01
+0 00
+0.95
-0 00
S
S
S
S
R
S
19
19
20
25 5
10 5
22
S
S
S
S
R
S
Sample No 3 A0 = 1 91 x 1C5, A2 5 = 8. 83 x 106
Ampiclllin
Cephalothln
Tetracyclme
Chloramphenlcol
Enythromycin
Gentamicin
+0 00
+0 01
+0 04
+0 03
+1.07
+0 02
S
S
S
S
R
S
19
19
20
25 5
10 5
22
S
S
S
S
R
S
Sample No. 4 A0 = 0 55 x 105, A2 5 = 5. 09 x 1C6
Ampiclllin
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamicin
-0 00
-0.00
+0.03
+0.03
+0 86
-0 00
S
S
S
S
R
S
19
19
20
25.5
10 5
22
S
S
S
S
R
S
Sample No. 5 A0 = 0 20 x 1C5, A2 5 = 2 17 x 107
Ampicillm
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamicin
+0 00
+0 01
+0 01
+0.01
+0 80
+0 00
S
S
S
S
R
S
18
19
20
25 5
10.5
22
S
S
S
S
R
S
Sample No 6 A0 = 3 65 x 105, A25 = 5 .94x l0 7
Ampicilhn
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamicin
-0 00
-0 00
+0.01
+0 00
+0 93
-0 00
S
S
S
S
R
S
19
19
20
25 5
10.5
22
S
S
S
S
R
S
Sample No. 7 A0 = 3 06 x 105, A2 5 = 1.49 x 105
Ampiclllin
Cephalothln
Tetracycline
Chloramphenico]
Enythromycin
Gentamicin
-0.88
-0 85
+0 31
+0 06
+0 17
-0 79
S
S
R
R
S
S
19
19
20
25.5
10.5
22
S
S
S
S
R
S
false R
false R
false R
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Table 5-2 (Continued)
Sample No 8 A0 = 3. 75 x 106, A2 5 = 5. 88 x 107
Amplcilltn
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamlcln
+0.01
-0.05
+0 02
-0.00
-0.52
-0 06
S
S
S
S
R
S
19
19
20
25.5
10.5
22
S
S
S
S
R
S
Sample No 9 A0 = 1. 16 x 106, A2. 5 = 7 92 x 107
Amplcillin
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamlcin
-0 01
-0.01
+0.01
-0.00
+0.03
-0.01
S
S
S
S
R
S
19
19
20
25 5
10.5
22
S
S
S
S
R
S
false S
Sample No. 10 A0 = 3.69 x 105; A2.5 = 1.45 x 106
Amplcillin
Cephalothin
Tetracycline
Chloramphenicol
Enythromycin
Gentamicln
+0.11
+0.08
+0 05
+0 10
+0.33
-0 04
R
R
S
R
R
S
19
19
20
25.5
10.5
22
S
S
S
S
R
S
false R
false R
false R
Sample No. 11 A0 = 1.24xlo
6
, A25 = 3 .64xl0 7
Amplcillin
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamlcln
-0.02
-0.02
-0.00
-0.00
+1.02
-0.03
S
S
S
S
R
S
19
19
20
25.5
10.5
2?
S
S
S
S
R
S
Sample No. 12 A0 = 6 05 x 105, 1.23xl08 \
Amplcillin
Cephalothln
Tetracycline
Chloramphenicol
Enythromyctn
Gentamlcin
-0.00
-0.00
+0 00
+0.00
+0 09
-0 00
S
S
S
S
R
S
19
19
20
25.5
10 5
22
S
S
S
S
R
S
Sample No. 13 A0 = 5. 40 x 105, A2. 5 = 9. 80 x 107
Amplcillin
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamtcln
-0.01
-0 01
+0.01
+0.00
+0.77
-0.01
S
S
S
S
R
S
19
19
20
25.5
10 5
22
S
S
S
S
R
S
Sample No. 14 AQ = 7 37 x 105, A2. 5 = 1.33 x 108
Amplctllln
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamlcin
-0.03
-0 03
+0 00
+0.00
+0.86
-0 03
S
S
S
S
R
S
19
19
20
25.5
10.5
22
S
S
S
S
R
S
Sample No 15 A0 = 4. 57 x 105, A2. 5 = 1. 24 x 108
Amplcillin
Cephalothln
Tetracycline
Chloramphenicol
Enythromycin
Gentamicin
-0.01
-0.01
-0.00
-0.00
+0.95
-0 01
S
S
S
S
R
S
19
19
20
25.5
10.5
22
S
S
S
S
R
S
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patient was taking an antibiotic. In sample 1, the patient was on both ampicillin and oxa-
cillin, in sample 7, the patient was on cephalothin, and in sample 10, the patient was on
penicillin. In each case there was little or no growth in the growth control as seen by com-
paring A0 and A2 s values. Three samples from patients on antibiotics gave 100-percent
correlation: sample 5 was from a patient on cephalothin and samples 6 and 14 were from
patients on cefazolin.
Discussion
The excellent correlation obtained when patients were not on antibiotics indicates that ma-
terial accompanying the bacteria in the sediment does not interfere with sensitivity tests.
A variety of medications were taken by patients whose urine samples gave 100-percent cor-
relation; these urine samples also exhibited a large range of osmolalities and pH.
In the case of the samples which disagreed, no other factor except the antibiotic usage by the
patient was identified. Antibiotic sensitivity tests by the ATP method were unsuccessful
because little or no growth of the organisms in the growth control occurred. Apparently,
even short exposure of the E. coll to the antibiotic in the urine before centrifugation inter-
fered with the subsequent growth after transfer to the broth.
Clearly, this is an artificial system. In the clinical situation, a patient (would not develop a
urinary tract infection with an organism sensitive to an antibiotic being administered. If a
urinary tract infection did arise in this situation, the organisms would be resistant, growth
would occur in the growth control, and ATP sensitivity testing could probably be carried
out.
PRELIMINARY EVALUATION OF METHOD ON CLINICAL URINE SAMPLES
The foregoing work had established that: (1) centrifugation could be used to isolate bacteria
from the urine; (2) an inoculum of 1 X 105 organisms/ml gave satisfactory results and could
be achieved from urines with 30,000 organisms/ml; and (3) urine and material contained in
the urine did not interfere with susceptibility tests (the only exception being when the urine
contained an antibiotic to which the organism was sensitive, a situation which should not be
encountered clinically).
At this point, it was feasible to begin a preliminary clinical trial. It would be desirable to
obtain urines known to be infected with a single organism at a level of 30,000 organisms/ml
or greater, A method to obtain such samples was devised.
Urine specimens were received by the NEMCH Microbiology Laboratory and immediately
refrigerated. Near the end of a working day, all samples were inoculated onto an Eosin
Methyline Blue (EMB) blood agar plate with a 0.001-ml loop for colony counting and isola-
tion. The original urine sample was refrigerated. By examining plates in the morning, urines
with single organisms, 30,000 organisms/ml or greater could be identified. The original urine
samples could then be obtained from the refrigerator and used for ATP susceptibility testing.
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Experimental Plan
Samples were obtained as described previously. Forty-five ml of the urine sample were centri-
fuged at 8000 RCF X G for 15 minutes at 4°C. The supernate was decanted, and the tube was
allowed to drain in the upright position for approximately 30 seconds. The bacterial sedi-
ment was reconstituted with 15 ml of TSB.
To establish an appropriate inoculum size, an initial ATP assay of the reconstituted sample
was performed at this time. Of the 15-ml sample, 0.5 ml was subjected to ATP assay by the
nonconcentrated procedure without malic acid as described earlier in this report. On the
basis of the ATP level obtained, a dilution was earned out to give an A0 ATP level of approx-
imately 1 X 106 light units, which was shown by standard plate counts to correspond to an
inoculum of approximately 1 X 106 organisms/ml. The dilution was carried out with ad-
ditional TSB. Naturally, if the initial ATP assay produced less than 1 X 106 or approximately
1 X 106, no dilution step was employed.
For example, an initial ATP level of 2.27 X 108 light units was diluted 1:100 with TSB which
resulted in an AO of 2.05 X 106 light units; an initial ATP level of LI4 X 107 light units was
diluted 1:10 which resulted in an AQ of 8.54 X 10s light units.
At this point, the susceptibility testing was carried out as described in the first section.
Results
The results of 24 preliminary clinical samples are given in table 5-3. The sample number,
laboratory number, organism name, and number of bacteria per ml as determined by plate
count are given. Light units for the AQ and A2 s growth controls are given in the upper left
for each sample. The far left column gives the antibiotic being tested (final concentration
for each antibiotic has been listed previously). The column labeled Index gives the ATP
index calculated as described previously (without the use of logs). The next column, labeled
ATP Interpretation, assigns resistance (R) if the index is greater than 0.05 and sensitivity (S)
if the index is less than or equal to 0.05. The column headed Laboratory Results gives results
obtained from standard Kirby-Bauer agar diffusion susceptibility testing performed by the
j NEMCH Microbiology Laboratory. The column marked Usable indicates, by a negative sign,
when a particular determination was not included in final statistical analyses. In this prelim-
inary work, a determination was not used when the Kirby-Bauer method gave indeterminate
results. The problem of correlating indeterminate results with ATP results will be considered
later. A total of usable determinations for each sample is given at the bottom of this column.
The last column gives an indication of when the ATP results and Kirby-Bauer results disagreed.
A false-sensitive (S) means that the Kirby-Bauer result was resistant and the ATP result was
sensitive. A false-resistant (R) means that the Kirby-Bauer result was sensitive and the ATP
result was resistant.
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Table 5-3
Results of Preliminary Clinical Trial of the ATP Method for Determining
Antibiotic Susceptibilities Using the Nonconcentrated Procedure
without Malic Acid to Estimate Inoculum Size
Antibiotic Index
ATP
Interpretation
Laboratory
Results Usable
Disagreement
with Laboratory
Sample No. 1 Laboratory No. 160
50,000 £ coll, < 10, 000 cohform AQ =1 Six 106 A2.5 = 1. 14 x 10
Penicillin
Ampicillm
Nafcillin
Carbemcillin
Cephalothin
Tetracyclme
Chloramphemcol
Clmdamycm
Erythromycm
Gentamicin
Colistin
+1.08
+1.01
+1.12
+1.13
-0.01
+0.80
+1.16
+1.27
+0.86
-0.01
-0 01
H
R
R
R
- ' s
R
R
R
R
S
S
R
R
I
R
R
R
S
S
—
—
—
—
Total = 7
Sample No. 2 Laboratory No. 170
20-40,000 Klebsiella, <10,000 Proteus A0 = 1.49 x 10 A2 - 5 = 3.75 x 10?
Penicillin
Ampicillm
Nafcillin
C arbemcillin
Cephalothin
Tetracyclme
Chloramphemcol
C hndamycin
Erythromycin
Gentamicin
Cohstln
+0.96
+0.87
+0 89
+0.64
-0.02
-0.02
-0.02
+0.88
+0.81
-0.03
-0.02
R
R
R
R
S
s
s
R
R
S
s
R
R
S
S
s
R
S
S
—
—
—
Total = 8
Sample No. 3 Laboratory No. 185
> 100, 000 E coll, 10-30,000 Proteus A0 = 2 44 x 10 A2.s = 1.71 x 108
Penicillin
Ampicillm
Nafcillin
Carbemcillin
Cephalothin
Tetracyclme
Chloramphemcol
Clmdamycm
Erythromycin
Gentamicin
Colistin
+1.35
-0.01
+1 33
-0.01
-0.01
10.19
+0.02
+1.52
+1.35
-0.01
+0.20
R
S
R
S
s
R
s
R
R
S
R
R
S
S
S
s
R
S
S
—
—
—
Total = 8
(false R)
(false R)
Sample No. 4 Laboratory No 168
40,000 £ coli, <10,000 gram negative A0 = 7.04 x 10 A2 5 = 1. 14 x 10
Penicillin
Ampicillm
Nafcillin
Carbenicillm
Cephalothin
Tetracyclme
Chloramphemcol
Clmdamycm
Erythromycin
Gentamicin
Colistin
+0 69
+0.30
+0.73
+0.28
+0.01
+0.01
+0 00
+0.73
+0.56
+0 04
+0.03
R
R
R
R
S
S
s
R
R
S
S
R
S
S
S
s
R
S
s
—
—
—
Total = 8
(false R)
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Table 5-3 (Continued)
Antibiotic Index
ATP
Interpretation
Laboratory
Results Usable
Disagreement
with Laboratory
Sample No 5 Laboratory No. 593
>100. 000 Klebsiem~ A0 = 1. 66 x 106 A2. 5 = 1. 28 x 108
Penicillin
Amplcillin
Nafcillin
CarbeniclUfn
Cephalothin
Tetracyclme
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Coliatin
+1.24
+1.47
+1.55
+1.25
-0.01
-0.00
-0.01
+0.98
+1.23
-0.01
-0.01
R
R
R
R
S
S
S
R
R
S
S
R
R
S
S
S
R
S
S
—
_
—
Total = 8
Sample No. 6 Laboratory No 674
50-100,000 E coll AO = 7 89 x 106 A2 5 = 2.80 x 108
Penicillin
Ampicillin
Nafcillin
Carbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Coliatin
+1.33
-0.02
+0.99
-0.02
+0.05
+0.04
+0.03
+1.00
+0.95
-0.02
-0.03
R
S
R
S
S
S
S
R
R
S
S
R
S
S
S
S
R
S
S
—
—
—
Total = 8
Sample No. 7 Laboratory No. 636
>100, 000 Enterococcus A0 = 2. 64 x 106 A2 5 = 1. 14 x 108
Penicillin
Amplcillin
Nafcillin
CarbeniciUin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Coltsttn
-0.01
-0.15
+1.18
-0.01
+0.22
+0.74
+0.03
+0.19
+0.03
+0.59
+1.11
S
S
R
S
R
R
S
R
S
R
R
R
S
R
S
S
R
R
R
—
—
—
Total = 8
(false S)
(false R)
Sample No. 8 Laboratory No 641 8
> 100, 000 E coh, < 10, 000 Enterococcus A0 = 3.04xl06 A2 5 = 2.42 x 108
Penicillin
Ampicillin
Nafcillin
Carbentclllin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistln
+0.95
-0.01
+0.99
-0.01
-0.01
+1.00
+0.01
+1.00
+0.82
-0.00
+0.02
R
S
R
S
S
R
S
R
R
S
S
R
S
S
R
S
R
S
S
—
—
—
Total = 8
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Table 5-3 (Continued)
Antibiotic Index
ATP
Interpretation
Laboratory
Results Usable
Disagreement
with Laboratory
Sample No. 9 Laboratory No. 743 8
> 100, 000 E coll 30-50,000 Klebsiella Afl = 1.55 x 106 A2>5 = 1. 65 x 108
Penicillin
AmplcilllD
Natcillln
Carbenlclllln
Cephalothln
Tetracycllne
Chloramphemcol
Cllndamycln
Erythromycln
Gentamlcln
Collstln
+0.91
+0 00
+0.88
-0 01
+0.01
+0.02
+0.01
+0.93
+0.93
-0.01
-0 01
R
S
R
S
S
S
S
R
R
S
S
R
S
S
S
S
R
S
S
—
_
—
Total = 8
Sample No. 10 Laboratory No. 763
> 100, 000 P mirabilis AO = 8.54 x 1Q5 A2-5 = 5.72 x 107
Penicillin
Amplclllln
Nafclllln
Carbenlclllln
Cephalothm
Tetracycllne
Chloramphenicol
Cllndamycin
Erythromycln
Gentamlcln
Collstln
+0.01
+0.04
+0.84
-0.00
+0.05
+0.71
+0.01
+0.85
+1.00
+0.04
+0.73
S
S
R
S
S
R
S
R
R
S
R
I
S
S
S
S
R
S
R
—
_
—
Total = 7
(false R)
Sample No. 11 Laboratory No. 713 7
> 100,000 Pseudomonas AQ = 3.08 x 105 A2g 5 = 7 49 x 10s
Penicillin
Amplclllln
Nafclllln
Carbenlclllln
Cephalothln
Tetracycllne
Chloramphenicol
Cllndamycin
Erythromycin
Gentamicin
Coltstln
+0.32
+0.34
+1.00
+0.74
+0.64
+1.36
+0.66
+2.77
+2.86
+0.41
+0.52
R
R
H
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
S
—
_
—
Total = 8 (false R)
Sample No. T2~ Laboratory No. 211 8
> 100, 000 E coh < 10,000 Mucoid Coltform A0 = 2 .01xlo 6 A2.s = 3.00x 108
Penicillin
Amplclllln
Nafclllln
CarbenlclUln
Cephalothln
Tetracycllne
Chloramphenicol
Cllndamycin
Erythromycln
Gentamlcln
Collstln
+0.79
+0.00
+0.87
+0.00
+0.03
+0.86
+0.01
+0.80
+0.74
-0.01
-0.01
R
S
R
S
S
R
S
R
R
S
S
R
S
S
R
S
R
S
S
—
—
—
Total = 8
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Table 5-3 (Continued)
Antibiotic Index
ATP
Interpretation
Laboratory
Results Usable
Disagreement
with Laboratory
Sample No 13 Laboratory No. 234
>100,000 P mirabilis Afl = 1. 60 x 107 A2 g = 3. 25 x 108
Penicillin
Ampicillin
NafcilHn
Carbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Chndamycln
Erythromycin
Gentamicin
Collstln
-0.04
-0 04
+1.12
-0.04
-0.03
+0.98
-0.01
+1.03
+1.06
-0.04
+1.05
S
S
R
S
S
R
S
R
R
S
R
I
S
S
R
S
R
S
R
_
_
_
Total = 7
Sample No. 14 Laboratory No. 420
> 100, 000 E coll A0 = 1.99 x 106 A2 g = 1.96 x 108
Penicillin
Ampicillin
Nafcillm
Carbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Cllndamycin
Erythromycin
Gentamicin
Colistin
+0.98
+0.001
+1.12
-0.01
+0.06
+0.01
+0.01
+1.05
+0.95
-0.01
-0.01
R
S
R
S
R
S
S
R
R
S
S
R
S
S
S
S
R
S
S
_
_
Total = 8
(false R)
Sample No 15 Laboratory No. 412
50-100,000 Klebsiella A Q = 5 . 3 0 x 105 AZ g = 1. 96 x 107
Penicillin
Ampicillin
Nafcillm
CarbeniciUin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Coliatln
+1 08
+0.40
+0.98
+0.17
' -0 00
+0.03
+0.03
+0.86
+0.87
-0.00
-0 01
R
R
R
R
S
S
S
R
R
S
S
R
R
S
S
S
R
S
S
_
_
_
Total = 8
Sample No. 16 Laboratory No. 492
> 100, 000 P morganu AQ = 7. 68 x 105 A2 5 = 1. 40 x 10
Penicillin
Ampicillin
NafcilHn
Carbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Collstln
+1.52
+1.10
+1.32
-0.04
+1.47
-0.03
-0.03
+1.17
+1.19
-0.04
+1.26
R
R
R
S
R
S
S
R
R
S
R
R
R
R
S
S
R
S
R
—
_
—
Total = 8
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Table 5-3 (Continued)
Antibiotic Index
ATP
Interpretation
Laboratory
Results Usable
Disagreement
with Laboratory
Sample No. 17 Laboratory No. 505
>100,000 E coll Afl =4.74 x 106 Ag g = 1.75 x 108
Penicillin
Ampicillin
Nafcillin
Carbemcillm
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
+1.47
-0.01
+1.29
-0.03
+0.01
+0.02
+0.01
+0.77
+0.73
-0.03
-0.03
R
S
R
S
S
S
S
R
R
S
S
R
S
S
S
S
R
S
S
—
—
—
Total = 8
Sample No 18 Laboratory No. 763
> 100, 000 £ coh A 0 =4 .78 x 10s A2-5 = 2 61 x 108
Penicillin
Ampicillin
Nafcillin
C arbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
+1.14
-0.02
+0.97
-0.02
-0.02
+0.97
+0.02
+0.94
+0.98
-0.02
-0.02
R
S
R
S
S
R
S
R
R
S
S
R
S
S
R
S
R
S
S
—
—
—
Total = 8
Sample No. 19 Laboratory No 785
> 100, 000 P morgana AO = 1 65 x 106 A2. 5 = 4. 75 x 10?
Penicillin
Ampicillin
Nafcillin
C arbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Cohstin
+1.24
+1.26
+1.14
-0.02
+1.21
+1.00
+0.15
+1.27
+1.06
-0.03
+0.97
R
R
R
S
R
R
R
R
R
S
R
R
S
R
R
R
R
S
R
—
—
—
Total = 8
(false R)
Sample No 20 Laboratory No. 812
>100,000 Qtrobacter ferundn A0 = 2. 14 x H>6 A2. 5 = 2. 10 * 108
Penicillin
Ampicillin
Nafcillin
C arbenicillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
+0.77
+0.01
+0.86
-0.01
+0.00
+0.02
+0.03
+0.94
+0.94
-0.01
-0.01
R
S
R
S
S
S
S
R
R
S
S
R
S
R
S
S
R
S
S
—
—
—
Total = 8
(false S)
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Table 5-3 (Continued)
Antibiotic Index
ATP
Interpretation
Laboratory
Results Usable
Disagreement
with Laboratory
Sample No. 21 Laboratory No. 881
> 100, 000 E coh AQ = 1.69 x 106 AZ g = 2.79 x 108
Penicillin
Ampicillin
Nafcillm
Carbenicillin
Cephalothin
Tetracyclme
Chloramphemcol
Clindamycin
Erythromcin
Gentamicin
Colistin
+0.91
-0.00
+0.90
-0.01
-0.00
+0.02
+0.02
+0.84
+0.66
-0 01
-0.01
R
S
R
S
S
S
S
R
R
S
S
R
S
S
S
S
R
S
S
—
_
Total = 8
Sample No. 22 Laboratory No. 891
>100,000 Candida >100, 000 P morgami Afl = 1.42 x 106 A2.g = 6. 54 x 107
Penicillin
Ampicillin
Nafctllin
Carbenicillin
Cephalothin
Tetracyclme
Chloraxnphenicol
Clindamycin
Erythromycin
Gentamicin
Coliatin
+0.92
+0.80
+0.92
+0.01
+0.69
+0.82
+0.21
+0.95
+0.82
+0.17
+0.89
R
R
R
S
R
R
R
R
R
R
R
R
R
R
R
R
R
S
R
—
_
—
Total = 8
(false R)
Sample No 23 Laboratory No. 900 8
> 100,000 E coll 50-100,000 Enterococcus A0 = 9.44 x 106 A2 5 = 5.46 x 108
Penicillin
Ampicillin
Nafcillm
Carbenicillin
Cephalothin
Tetracyclme
Chloramphemcol
Clindamycin
Erythromycin
Gentamicin
Colistin
+0.83
-0.00
+0 92
-0.02
+0.01
+0.03
+0 01
+0.98
+0.75
-0.01
+0.01
R
S
R
S
S
S
S
R
R
S
S
R
S
S
S
S
R
S
S
—
_
—
Total = 8
Sample No 24 Laboratory No 122
>100,000 P mirabilts A0 = 0 .06x l0 5 A2. 5 = 1. 31 x 106
Penicillin
Ampicillin
Nafcillm
Carbenicillin
Cephalothin
Tetracyclme
Chloramphemcol
Clindamycin
Erythromycin
Gentamicin
Cohstin
+0.82
+0.09
+0.53
+0.00
+0.21
+0.33
+0.01
+1.31
+1.55
+0.27
+0.94
R
R
R
S
R
R
S
R
R
R
R
I
S
I
R
S
R
S
R
—
—
—
—
Total = 6
(false R)
(false R)
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Discussion
Twenty-four samples were run with a total of 187 usable antibiotic determinations. Overall
correlation was 93.1 percent between the Kirby-Bauer method and the ATP method.
Nine samples had mixed infections; agreement for this subgroup was 94.4 percent. Three
patients were on antibiotics, and agreement for this group was 87.5 percent. Patient 7 was
on kanamycin, patient 11 was on gentamicin, and patient 16 was on ampicillin. Evaluation
of this potential problem will require more samples for statistical significance.
Analysis of errors by individual antibiotics indicated that ampicillin had the greatest number.
Three of the 12 total errors were with ampicillin. Two were with Proteus and one was with
> 100,000 per ml E coli accompanied by < 10,000 per ml of another coliform. Two errors
each were encountered for cephalothin, tetracycline, gentamicin, and colistin. Penicillin had
one error.
The ampicillin -Proteus combination difficulty had been encountered in previous work and is
thought to be dependent on the mechanism of action of ampicillin. Possibly this problem
could be corrected by prolongation of incubation time to 3 hours.
Conclusions
The preliminary work successfully established the following points:
• That organisms could be isolated from the urine for subsequent susceptibility
testing using centrifugation
• That appropriate inocula could be established by using an initial ATP assay
• That a high correlation between the Kirby-Bauer method and the ATP method
could be obtained using urine samples directly
• That samples with two organisms, in which one organism predominated, could
be evaluated with ATP methods
USE OF AN ATP ASSAY (THE LONG CENTRIFUGATION METHOD) SUITABLE FOR
DETECTION OF BACTERIURIAS TO ESTABLISH APPROPRIATE INOCULUM SIZE
FOR SUSCEPTIBILITY TESTING
In the preliminary clinical work, an initial ATP assay was necessary to establish appropriate
inoculum size for subsequent antibiotic susceptibility testing. An eventual goal of the ATP
work is to first employ the ATP assay for detection of significant bacteriunas and then to
apply susceptibility testing when a significant infection is found. Qearly, it would be desir-
able if information from the initial detection ATP assay could be used to produce appropriate
inoculum sizes for subsequent susceptibility testing. Considerable time and expense could be
saved if the centrifugation step required in the detection ATP assay also could be used to
isolate bacteria for subsequent susceptibility tests. A method to achieve these goals was
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devised. Figure 5-3, a flow chart of the method, indicates the performance of two procedures:
detection of bacteriuria on the left and susceptibility testing on the right. The first centrifu-
gation (below urine sample) serves as the first centrifugation step for the ATP assay used for
detection and also serves to isolate bacteria from the urine for subsequent susceptibility test-
ing.
URINE SAMPLE
CENTRIFUGATION
RECONSTITUTION OF BACTERIA ISOLATED
IN SEDIMENT IN SMALL VOLUME OF BROTH
DETECTION ALIQUOTS SUSCEPTIBILITY
PRETREATMENT
TO REMOVE
NONBACTERIAL ATP
CENTRIFUGATION
ATP DETERMINATION — APPROPRIATE
DILUTION OF ISO-
LATED BACTERIA
ON BASIS OF ATP
DETERMINATION
FROM DETECTION
SIDE
ANTIBIOTIC
SUSCEPTIBILITY
TESTING BY ATP
METHOD
Figure 5-3 Flow chart of long centrifugation procedure for ATP assay.
After initial centrifugation, the detection assay is completed. If a significant bacteriuria is
detected, susceptibility testing is carried put; if not, work on that sample is completed. The
ATP level from the detection assay is used to calculate appropriate dilution of the bacterial
sediment to achieve desired inoculum size.
The details of the procedures are as follows. Presently the most sensitive detection assay
with best discrimination between bacterial ATP and nonbacterial ATP is the long centrifu-
gation procedure (Chappelle et al., 1975). The detection procedure used here is the slightly
modified long centrifugation procedure. In this method, 35 ml of the urine sample is cen-
trifuged at 8000 RCF X G for 15 minutes at 4°C, and the sediment is suspended in 1.75 ml
of TSB. Of this 1.75 ml, 0.5 ml is then used to complete the long centrifugation procedure.
This 0.5 ml represents the sediment obtained from 10 ml of urine which is the amount called
for in the long centrifugation procedure. In the established long centrifugation procedure,
Triton X-100 (TX) is added prior to the initial centrifugation step. Rather than expose
bacteria that will be used in subsequent susceptibility testing to TX, we have chosen to add
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the TX along with the apyrase after the initial centrifugation. This should have an equivalent
effect at this point in the assay. The remainder of the assay is performed according to the
established technique. The exact manipulations are given in Procedures 1 and 2 in Appendix
B.
Establishing Appropriate Inoculum for Susceptibility Testing
The ATP level obtained from the detection assay was then used to establish an appropriate
inoculum size for susceptibility testing.
Based on the ATP level obtained, a certain dilution was carried out. An inoculum size of at
least 1 X 10s organisms/ml, but not much greater than 1 X 106 organisms/ml, was needed
for susceptibility testing. Previous work indicated that these inoculum sizes corresponded
to about 1 X 10s to 1 X 107 light units for the AQ's by the nonconcentrated procedure with-
out malic acid. A dilution schedule to achieve this range of A0 based on the results from the
long centrifugation procedure was established. The details of how this dilution schedule was
established are given in Experiment 4 in Appendix B. The dilution schedule is given in table
5-4.
Table 5-4
Dilution Schedule to Achieve Desired Inoculum Size
Long Centrifugation
ATP Levels (light units)
Desired Change from
the Original Bacterial
Level in the Urine
Actual Manipulation
of 1.2 5 ml Aliquot
(which already represents
a 20-fold concentration
of the original urine)
1.0 X 106
1.0 X 106 - 1.0 X 108
1.0 X 108 -3.0X 108
3.0 X 108 - 3.0 X 109
3.0 X 109
No significant bacteria
3-fold concentration
No change from original
level
10-fold dilution
100-fold dilution
Stop procedure
6-fold dilution
20-fold dilution
200-fold dilution
2000-fold dilution
The AQ's achieved with this dilution schedule are given in the results of the further clinical
trials. The great majority of AO'S were in the desired 1 X 10s to 1 X 107 light unit range.
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ADDITION OF KANAMYCIN AND STREPTOMYCIN TO ANTIBIOTICS BEING
EVALUATED
The Microbiology Laboratory at NEMCH includes kanamycin and streptomycin in antibiotic
susceptibility testing for urinary pathogens. Kirby-Bauer results would be available from the
Microbiology Laboratory for each sample. Therefore, it was desirable to include these anti-
biotics in further clinical trials of the ATP method.
An approach similar to that employed by Dr. Vellend (described in Section 4 of this docu-
ment) was used. An appropriate antibiotic concentration was sought first. Concentrations
that represented the MIC breakpoint for resistant and susceptible strains, and a concentration
midway between these values were evaluated against the previously employed reference
strains. Using these results, the following concentrations were chosen for additional evalu-
ation: 15 Atg/ml of kanamycin and 10 jug/ml of streptomycin.
Details of the experiments used to arrive at these values are given in Experiment 3 in Appen-
dix B. Additional evaluation of various strains would take place as part of the clinical trial.
The correlation achieved for these antibiotics with Kirby-Bauer results would indicate the
appropriateness of these concentrations.
MODIFICATION OF CERTAIN TECHNICAL ASPECTS OF THE METHODS TO INCREASE
EFFICIENCY AND ACCURACY
Antibiotics, when originally made up at 2^week intervals, were diluted to appropriate con-
centrations with sterile distilled water, aliquoted into individual polypropylene tubes that
were suitable for ATP assay, and frozen. On the day of use, it was a matter of selecting ap-
propriate previously aliquoted tubes rather than pipetting individual aliquots each day.
Rather than use.0.1 ml of antibiotic solution and 0.9 ml of broth with bacterial inoculum,
0.05 ml of antibiotic solution (or distilled water for growth control) and 0.45 ml of broth
were chosen. This change would allow the assay to be performed by addition of reagents,
without having to withdraw 0.5 ml into a separate tube. The modification represents a con-
siderable savings of time and equipment (pipettes and polypropylene tubes), and probably
improves accuracy.
Rather than prepare luciferase twice and perform separate ATP assays for AQ's, the samples
were taken through the addition of apyrase, nitric acid, and distilled water, and then stored
at room temperature until A2 s and Bt J2, were ready for assaying. All samples were then
assayed using the same! lucif erase; preparation. Experiments to confirm the stability of the
extracted and diluted bacterial ATP in the AQ were performed. The details are given in
Experiments 1 and 2 in Appendix B. The ATP levels did not change significantly after even
5 hours for any of the reference organisms tested. This modification conserved luciferase
and perhaps increased accuracy by employing the same luciferase for corresponding AQ's,
A2S's, and B's.
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FURTHER EVALUATION OF CLINICAL URINE SAMPLES AND DETAILED ANALYSIS
OF ERRORS
This evaluation of clinical urine samples employed the changes discussed above: the use of
the long centrifugation method, the addition of kanamycin and streptomycin, and other
modifications. The exact manipulations of samples are given in Procedures 1 and 2 in Appen-
dix B. Samples were selected in the manner described in Section 4.
Results
Table 5-5 gives the results of 42 clinical specimens. The format is similar to that used in tables
5-2 and 5-3.
Particular caution was exercised in recording Kirby-Bauer data. The column labeled KB gives
measurements of zones of inhibition obtained from standard Kirby-Bauer agar diffusion sus-
ceptibility testing as performed by'the NEMCH Microbiology Laboratory. The column
labeled KB Interpretation gives the interpretations of the Kirby-Bauer results based on meas-
ured disc diameters. In table 5-6, the standard criteria used for assigning Resistant or Sen-
sitive on a basis of zone diameters are given. Diameters falling between critical values for
resistance and sensitivity are considered indeterminate. The column labeled Lab Results is
the Microbiology Laboratory interpretation of the Kirby -Bauer zones. This is based on an
estimate of zone sizes and not on precise measurements as we took them. In difficult cases
where zone sizes were near the cutoff points, errors could certainly arise because of such
estimates. In these cases, our measured results were accepted as correct.
In the column labeled Usable, a negative sign indicates when a particular determination was
not used in calculations. When the Kirby-Bauer method gave indeterminate results, the point
was not included in initial analyses of the data. If the Kirby-Bauer method performed by the
NEMCH Microbiology Laboratory disagreed with the Kirby-Bauer method performed by us
(indicated by an asterisk) the point was generally not used. However, if our Kirby-Bauer
interpretation agreed with the ATP interpretation, the point was accepted. The usable total
for each sample is given at the bottom of this column. The last column, Disagreement, indi-
cates disagreement between the ATP interpretation and the Kirby-Bauer interpretation. Kirby-
Bauer results are accepted as correct. Therefore, if the Kirby-Bauer result was sensitive and
ATP result was resistant, this was called false^esistant (false R). If the Kirby-Bauer result
was resistant and the ATP result was sensitive, this was called false-sensitive (false S).
Discussion of Results
Considering the entire group of 42 samples, the correlation between Kirby-Bauer results and
ATP results was 92.5 percent. Of the 42 samples, 7 were mixed infections as indicated on
the individual charts in table 5-5. Agreement for the 35 nonmixed samples was 92.9 percent
with 365 total determinations and 26 errors.
It is best to consider the nonmixed and mixed samples separately in an attempt to analyze
sources of errors. Mixed infections here gave a similar degree of correlation; nonetheless,
the presence of more than one organism could introduce an intrinsic source of error.
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Table 5-5
Results of Clinical Trial of Final Proposed ATP Method for Determining
Antibiotic Susceptibilities Using Long Centrifugation Procedure for
Establishing Inoculum Size and Testing Additional Antibiotics
A ntibiotic Index
ATP
Interpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No 967 AO = 3 60 x 106, A2 5 = 2 23 x Ifl5
>100,000 P mirabilis, <10, 000 cohform
Penicillin
Ampicillm
Nafcilhn
Carbenicillm
Cephalothm
Tetracychne
Chloramphenicol
Chndamycm
Erythroraycm
Gentamicin
Cohstm
Kanamycin
Streptomycin
Nitrofurantom
+0.22
+0 12
+0.69
+0 31
-0 01
+0.40
+0.00
+0.76
+0 89
-0 01
+0 42
+0.12
R
R
R
R
S
R
S
R
R
S
R
R .
16
26
0
29
22
0
23
0
0
0
10.0
R
S
R
S
R
S
R
R
R
R
I
S
S
R
S
R
R
S
S
R
Usable Total =
1 (false R)
= 10
1
Sample No 946 A0 = 1 90 x 106, A2 5 = 2 30 x 108
>100,000 Kbesiella
Penicillin
Ampicillm
Nafcilhn
Carbenicillm
Cephalothm
Tetracychne
Chloramphenicol
Chndamycm
Erythromycm
Gentamicin
Cohstin
Kanamycin
Streptomycin
Nitrofurantom
+0.57
+0 18
+0.78
+0 76
-0 01
+0 02
+0 01
+0 83
+0.79
-0.01
+0.01
+0.01
R
R
R
R
S
S
S
R
R
S
S
S
10
19
0
21
27
23
30
0
13
16
23
R
S
R
S
S
S
R
R
S
S
S
R
S
S
S
S
R
S
S
S
S
S
1 (false R)
Usable Total = 11
Sample No. 040 AQ = 3.49 x 105, A2- 5 = 2. 10 x 108
>100,000 Klebsiella, <10,000 Proteus
Penicillin
Ampicillm
Nafcilhn
Carbencillin
Cephalothin
Tetracychne
Chloramphenicol
Chndamycm
Erythromycin
Gentamicin
Cohstin
Kanamycin
Streptomycin
Nitrofurantoin
+ 1.00
+ 1.00
+0.93
+0.97
-0.00
+0.01
+0.01
+0.91
+0.86
-0.00
-0.00
+0.00
R
H
R
R
S
S
S
R
R
S
S
S
0
10
0
10
22
20
25
0
10
15
18
R
R
R
S
S
S
R
R
S
S
R
H
S
S
S
R
S
S
S
S
Usable Total = 10
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No. 10 A0 =5 .30x 105, A2 5 = 5. 77 x 106
>100,000 Pseudomonas
Penicllltn
Amptcllllo
Nafcilltn
Carbenclllln
Cephalothln
Tetracycllne
Chloramphenlcol
CHndamycIn
Erythromycln
Gcntamicin
Colistin
Kanamycln
Streptomycin
Nltrofurantoin
+0.96
+1.07
+1.06
+0.59
+0.70
+0.31
+0.78
+1.25
+0.74
-0.05
-0.06
+0.75
R
R
R
R
R
R
R
R
R
S
S
R
0
0
0
0
0
0
0
0
15
0
R
R
R
R
R
R
R
R
S
R
R
R
R
R
R
R
S
R
I
R
Usable Total = 10
Sample No. 200 A0 = 4. 50 x 105, A2 5 = 5 04 x 10?
30,000 E coli
Penicillin
Ampiclllln
Nafcillln
Carbenclllln
Cepbalothln
Tetracyollne
Chloramphenlcol
Cllndamycln
Erythromycln
GentamlclD
Collstln
Kanamycln
Streptomycin
Nitrofurantoln
+0.93
+0.00
+0.85
+0.01
+0.00
+0.02
+0.02
+0.82
+0.66
+0.00
+0.00
+0 002
R
S
R
S
S
S
S
R
R
S
S
S
0
18
0
26
21
19
26
0
13
14
22'
R
S
R
S
S
S
S
R
R
S
S
R
S
S
S
S
R
S
S
S
S
Sample No. 229 A0 = 1.60 x 106, A2.s = 3.01 x 107
50 - 100,000 P mirabihs
Penicillin
Ampiclllln
Nafcillln
Carbenclllln
Cephalothln
Tetracycllne
Chloramphenlcol
Clindamycln
Erythromycin
Gentamlcin
Colistin
Kanamycln
Streptomycin
Nitrofurantoln
+0 00
-0.01
+1 12
+0.01
+0 01
+1 69
+0.02
+1.14
+0.99
+0.01
+0.84
+0.11
S
S
R
S
S
R
S
R
R
S
R
R
16
24
0
28
22
0
30
0
0
0
10
I
S
R
S
R
S
R
R
R
R
I
S
S
R
S
R
R
S
S
R
Usable Total = 9i
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No. 363, A0 = 5.07 x 105, A2- 5 = 1.37xl07
>100, 000 P rettgen
Penicillin
Amplcillln
Nafcillln
Carbenclllin
Cephalothin
Tetracycllne
Chloramphenicol
Cllndamycln
Erythromycln
Gentamicln
Colistln
Kanamycln
Streptomycin
Nitrofurantoln
+0.69
+0.29
+1.05
-0.02
+0.56
+1.06
+0.03
+0.98
+1.32
-0.01
+0.92
+0.95
R
R
R
S
R
R
S
R
R
S
R
R
0
19.5
0
20
0
9
0
0
0
0
R
S
R
S
H
R
R
R
S
R
R
R
S
S
R
R
R
S
R
S
S
R
(false R)
(false R)
Usable Total = 11
Sample No. 361, Afl = 3.63x 105, A2 5= 2.57 x 107
>100, 000 E coll '
Penicillin
Amplcillln
Nafcillln
Carbenclllin
Cephalothin
Tetracycllne
Chloramphenicol
Clindamycln
Erythromycln
Gentamicln
Colistin
Kanamycln
Streptomycin
Nitrofurantoin
+0.98
+0.07
+1.00
+0.12
+0.10
+0.02
+0.006
+0.96
+0.67
-0.00
-0.01
-0.005
R
R
R
R
R
S
S
R
R
S
S
S
»
R
S
S
•s
S
R
S
S
s
s
s
R
S
S
s
s
R
s
s
s
s
s
Usable Total =
(false R)
(false R)
9
Sample No. 584, A0 = 6.53 x 105, A£ g = 2 55 x lo6
> 100, 000 Proteus
Penicillin
Ampicillln
Nafcillin
Carbenclllin
Cephalothin
Tetracycllne
Chloramphenicol
Clindamycln
Erythromycin
Gentamicin
Colistln
Kanamycln
Streptomycin
Nitrofurantoln
+3 57
+2.80
+3.06
+3 23
+3.36
+0 88
+3.68
+2.36
+1.90
+2 99
+3.47
+1.52
+0.17
R
R
R
R
R
R
R
R
R
R
R
R
R
0
0
0
13
0
8
0
0
12
0
0
12
0
R
R
R
R
R
R
R
R
R
R
R
I
R
R
R
R
R
R
R
R
R
R
I
R
Usable Total = 12
Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No 640, AQ = 6 96 x 10s, A, , = 1.83 x 106
50, 000 - 100, 000 E coll, < 10, 000 CoHform
Penicillin
Ampiclllln
Nafcillln
Cephalothin
Tetracycline
Chloramphenicol
Cllndamycln
Erythromycln
Gentamlcln
Collstln
Kanamycm
Streptomycin
Nitrofurantoln
+0.92
+0.84
+1.00
-0.01
+0.79
-0.03
+0.75
+0.65
-0.09
-0.28
-0.12
-0.09
-0.28
R
R
R
S
R
S
R
R
S
S
S
S
S
0
0
0
21
0
21
0
12
26
17
22 5
16
20
R
R
R
S
R
S
R
R
S
S
S
S
S
R
R
S
R
S
R
S
S
S
S
S
Usable Total = 13
Sample No 650; AQ = 3 26 x 106, A2 5 = 1.42 x 108
>100,000 E colt
Penicillin
Ampicillin
Nafcillin
Cephalothln
Tetracycline
Chloramphenicol
Cllndamycin
Erythromycin
Gentamicin
Colistin
Kanamycln
Streptomycin
Nitrofurantoin
+1.00
+0.03
+0.94
-0.01
+0.02
+0.01
+2.22
+0.07
-0.02
-0.02
-0.01
R
S
R
S
S
S
R
R
S
S
S
10
22
0
22
21
27
0
15.5
24
15
22
16
23
R
S
R
S
S
S
R
I
S
S
S
S
S
R
S
S
S
S
R
S
S
S
S
S
(false R)
Usable Total = 11
Sample No. 739, A0 = 1 34 x 106, A2 5 = 9. 54 x 107
30,000-50,000 E coll, < 10, 000 Proteus and Enterococcus
Penicillin
Ampicillin
Nafcillin
Cephalothin
Tetracycline
Chloramphenicol
Cllndamycin
Erythromycln
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantoin
+1.04
-0.01
+0 84
+0.01
+0 02
+0.01
+0 99
+0.45
-0.01
+0 01
+0.01
+0.07
-0 01
R
S
R
S
S
S
R
R
S
S
S
R
S
0
13 5*
0
7*
0
23
0
0
14
o
I
R
R
R
S
R
R
S
0, 16* S
18
13.5
8
S
I
R
R
S
I
R
R
R
R
R
S
S
R
(false S)
(false S)
(false S)
Usable Total = 10
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No 749, A0 = 1 93 x 106, A2 5 = 7 16 x 107
>100,000 P rettgen
Penicillin
Ampicillin
Nafcillin
Cephalothin
Tetracychne
Chloramphenicol
Clindamycin
Erythromycin
Gentamycm
Cohstin
Kanamycin
Streptomycin
Nltrofurantoin
+0.71
+0 16
+0 90
+0 42
+0 92
+0 12
+0.98
+1.03
-0.00
+0 87
-0 01
-0.00
+0.84
R
R
R
R
R
R
R
R
S
R
S
S
R
10
22
0
22
0
12
0
0
19
0
25
18
R
S
R
S
R
R
R
R
S
R
S
S
R
R
S
S
R
R
R
S
R
S
S
R
(false R)
(false R)
Usable Total = 13
Sample No 978, A0 = 2. 77 x 105,A2-5 = 7 25 * 106
50 - 100,000 £ coll, <10,000 Diptheroids
Penicillin
Ampicillin
Nafcillin
Cephalothin
Tetracychne
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistm
Kanamycin
Streptomycin
Nltrofurantoin
+1.03
+0.92
+0 87
+0.07
+0 65
+0.03
+0.59
+0.48
-0.02
-0.03
+0.66
+0.73
-0 02
R
R
R
R
R
S
R
R
S
S
R
R
S
0
0
0
17
0
26
0
13
24
15
0
0
23
R
R
R
I
R
S
R
R
S
S
R
R
S
R
R
I
R
S
R
S
S
H
R
S
Usable Total = 13
Sample No 994, A0 = 9 14 x IflS, Ag s = 3.61 x 107
>100,000 £ coll
Penicillin
Ampicillin
Nafeillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistm
Kanamycin
Streptomycin
Nltrofurantoin
+0.99
-0.02
+1.15
-0.02
+0.01
+0.01
+0.94
+0.69
-0.02
-0.02
-0.02
+0.04
-0.02
R
S
R
S
S
S
R
R
S
S
S
S
S
0
18.5
0
21
21
28
0
13
25.5
16
23
18
20
R
S
R
S
S
S
R
R
S
S
S
S
S
R
S
S
S
S
R
S
S
S
S
S
Usable Total = 13
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No. 997, AO = 3 99 x 105, A2 5 = 2 12 x 107
>100,000 £ coll
Penicillin
Ampicilhn
Nafcilhn
Cephalothm
Tetracyclme
Chloramphenicol
Clindamycm
Erythromycin
Gentamicm
Cohshn
Kanamycin
Streptomycin
Nitrofurantom
+0 96
+0 91
+0 92
-0.01
+0.80
+0.02
+0.88
+0.83
-0.01
-0 01
+0 59
+0 88
-0.01
R
R
R
S
R
S
R
R
S
S
R
R
S
0
0
0
19
0
24
0
10
27
16.5
0
0
22
R
R
R
S
R
S
R
R
S
S
R
R
S
R
R
S
R
S
R
S
S
R
R
S
Usable Total = 13
Sample No 168, AQ = 2 72 x 106, A2 5 = 1 96 x 108
>100,000 £ coll, 30 - 50,000 P mirab'llis (E coll) (Proteus)
Penicillin
Ampicillin
NafcUlm
Cephalothm
Tetracyclme
Chloramphenicol
Clindamycm
Erythromycin
Gentaimcm
Colistm
Kanamycin
Streptomycin
Nitrofurantom
+0.98
+ 1.25
+1.06
-0.00
+0 82
-0.01
+ 1.02
+0.8S
-0.01
+0.01
-0.01
+1.09
-0.00
R
R
R
S
R
S
R
H
S
S
S
R
S
0
0
0
15
0
27
0
<18
25
16
22
9
23
R
R
R
I
R
S
R
I
S
S
S
R
. S
R I
R S
S S
R R
S S
R R
S S
S R
S S
R S
S R
Usable Total = 11
Sample No. 191, Ag = 4. 63 x 106, A2 5 = 6 69 x 1C7
>100,000 £ coll
Penicillin
Ampicillin
Nafcillm
Cephalothm
Tetracycline
Chloramphenicol
Clindamycm
Erythromycin
Gentamicin
Cohstin
KanamyciQ
Streptomycin
Nitrofurantoln
+1.47
+0.26
+1.48
+0.20
-0.01
-0.01
+1.17
+0.88
-0.07
-0.07
-0.03
+0.16
-0.03
R
R
R
R
S
S
R
R
S
S
S
R
S
8
22
0
23
21
25
0
16
22
17
18.5
17
27
R
S
H
S
S
S
R
I
S
S
S
S
S
R
S
S
S
S
R
S
S
S
I
S
Usable Tote
(false R)
(false R)
(false R)
il = 12
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No. 232, AO = 8.58 x 106, A2 5 = 3.34 x 108
>100,000 Klebsiella
Penicillin
Ampicillin
Nafclllm
Cephalothln
Tetracychne
Chloramphenlcol
Clindamycin
Erythromycin
Gentamicin
Colistln
Kanamycln
Streptomycin
Nltrofurantoin
+0.82
+0.78
+0.93
-0.03
+0.02
+0.02
+0.70
+0.39
-0.03
-0.03
-0.02
-0.01
-0.01
R
R
R
S
s
S
R
R
S
S
s
s
s
0
9
0
22
17
26
0
12
25
16
23
21
22
R
R
R
S
I
S
R
R
S
s
s
s
s
R
R
S
I
S
R
S
S
I
I
Usable Total = 12
Sample No. 256, AQ = 6 63 x 106, A2 5 = 2.44 x 108
>100, 000 Serratia marcesens
Penicillin
Ampicillin
Nafcillin
Cephalothln
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
^Gentamicin
Cohstin
Kanamycin
Streptomycin
Nltrofurantoin
+1.05
+1.09
+0.86
+0.76
+0.80
+0.06
+0.76
+0.87
+0.70
+0.49
+0.84
+0.76
+0.47
R
R
R
R
R
R
R
R
R
R
R
R
R
0
0
0
0
0
13*
0
9
9
0
0
0
10
R
R
R
R
R
I
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
Usable Total = 12
Sample No. 294, A0 = 5 94 x 106, A2 5 = 4.36 x 108
>100,000 Klebsiella
Penicillin
Ampicillin
Nafcillin
Cephalothln
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nltrofurantoin
+0.95
+0.78
+0.99
-0.01
+0 03
+0.04
+0 97
+0.88
-0.01
-0.01
-0.01
-0.01
+0 13
R
R
R
S
S
S
R
R
S
S
s
s
R
0
10
0
26
21
30
0
12.5
29
0*
26
17
19
R
R
R
S
S
S
R
R
S
R
S
S
s
R
R
S
S
s
R
S
s
s
s
(false R)
Usable Total = 12
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No. 466, A0 = 5.73 x 106, A2 5 = 2.16 x 108
XtOO.OOO E coll
Penicillin
Amplclllln
Nafclllln
Cephalothin
Tetracyohne
Chloramphenlcol
Clindamycin
Erythromycin
Gentamicin
Colistin
Kanamycln
Streptomycin
Nltrofurantoin
+1.15
-0.01
+0.92
-0 00
+1 11
+0.03
+1.19
+1.10
+0.08
-0.03
+0.14
+1.17
+0.82
R
S
R
S
R
S
R
R
R
S
R
R
R
0
19
0
22
8
27
0
12.5
27
16
24*
0
14
R
S
R
S
R
S
R
R
S
S
S
R
R
R
S
S
R
S
R
S
S
R
R
R
(false R)
Usable Total = 12
Sample No 504, AQ = 3.69 x 106, A2 5 = 2.82 x 108
>100,000 £ coli •
Penicillin
Ampiclllln
Nafcilltn
Cephalothin
Tetracycllne
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nltrofurantoin
+0.90
-0.01
+0.94
-0.01
+0.85
+0.00
+0.94
+0.84
-0.01
-0.01
-0.01
-0.01
-0.01
R
S
R
S
R
S
R
R
S
S
S
S
S
7
20
0
23
0
28
0
15
27
17
24
21
23
R
S
R
S
R
S
R
R
S
S
S
S
S
R
S
S
R
S
R
S
S
S
S
S
Usable Total = 13
Sample No. 512, AO = 3. 88 x 106, A2 5 = 1. 33 x 108
>100,000£ co/i
Penicillin
Amplcillln
Nafcilltn
Cephalothin
Tetracycllne
Chloramphenicol
Clindamycin
Erythromycin
Gentamlcin
Colistin
Kanamycln
Streptomycin
Nltrofurantoin
+0.98
-0.01
+0.88
+0.14
+0.94
+0.03
+0.90
+0.98
-0.02
-0 03
-0.02
+0.59
-0 01
R
S
R
R
R
S
R
R
S
S
S
R
S
0
14
0
21
0
28
0
15
30
18
29
0
24
R
S
R
S
R
S
R
I
S
S
S
R
S
R
S
S
R
S
R
S
S
S
R
S
(false R)
Usable Total = 12
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results
Disagreement
Sample No. 524, A0 = 1 36 x 107, A2 5 = 2 19 x 108
>100,000 E coli
Penicillin
Ampicilhn
Nafcilhn
Cephalothin
Tetracycllne
Chloramphenicol
Clindamycln
Erythromycin
Gentamicln
Colistin
Kanamycin
Streptomycin
Nitroftirantom
+0.99
+0.94
-0 05
+0.10
+0.01
+0 07
+0.88
+0.86
-0 06
-0 06
-0.05
-0.00
-0.02
R
R
S
R
S
R
R
R
S
S
S
S
S
0
20
0
25
25
28
0
15
28
18
26
22
24
R
S
R
S
S
S
R
I
S
S
S
S
S
R
S
S
S
S
R
S
S
S
S
(false R)
(false S)
(false R)
(false R)
Usable Total = 12
Sample No 751, A = 9 87 x 105, A2 5 = 4 32 x 107
>100,000 Klebsiella
•
Penicillin
Ampicillin
Nafcillin
Cephalothin
Tetraeycllne
Chloramphenicol
Clmdamycin
Erythromycin
Gentamlcin
Colistin
Kanamyctn
Streptomycin
Nitroftirantom
+1.47
+1.56
+1.48
-0 01
+0 04
-0.01
+1.52
+1.08
-0.01
-0.02
+0 02
+0.58
+0 13
R
R
R
S
S
S
R
R
S
S
S
R
R
0
10 5
0
25
15
28
0
12
28
17
25
10
18
R
R
R
S
I
S
R
R
S
S
S
R
S
R
R
S
R
S
R
S
S
S
R
S (false R)
Usable Total = 12
Sample No 774, A0 = 8 57 x 105, Ag g = 3.43 x 107
50 - 100, 000 P mirabihs
Penicillin
Ampicillin
Nafcillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Cohstin
Kanamycin
Streptomycin
Nitrofurantom
-0 01
-0.01
+1.01
+0 00
+0.84
-0.00
+1.02
+1.18
-0.01
+0 75
-0.01
+0.07
+0.36
S
S
R
S
H
S
R
R
S
R
S
R
R
19
26
0
.23
75
30
0
0
26
0
22
20*
9
I
S
R
S
R
S
R
R
S
R
S
S
R
I
S
R
S
R
S
R
S
S (false R)
R
Usable Total = 12
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
[nterpretation
Laboratory
Results
Disagreement
Sample No 795, A „ = 9 48 x 10s, A2 5 = 3 77 x 108
> 100, 000 E coll
Penicillin
Ampicillm
Nafcilhn
Cephalothin
Tetracyclme
Chloramphenicol
Clindamycin
Erythromycin
Gentamicm
Cohstin
Kanamycin
S treptomy cm
Nitrofurantom
+0.92
-0.01
+0.88
-0 00
+0.02
+0.02
+0.98
+0.92
-0.02
-0.03
-0.02
+0.02
+0.01
R
S
R
S
S
S
R
R
S
S
S
S
S
0
19
0
22
25
28
0
12 5
28
18
25
21
23
R
S
R
S
S
S
R
R
S
S
S
S
S
R
S
S
S
S
R
S
S
S
I
S
Usable Total = 13
Sample No 817, A0 = 2 30 x 107, A 2 , 5 = 5 00 x 108
MOO, 000 E coll
Penicillin
Ampicillm
Nafcilhn
Cephalothin
Tetracyclme
Chloramphenicol
Clindamycin
Erythromycin
Oentamicin
Colistm
Kanamycin
Streptomycin
Nitrofurantoin
+1.04
-0.02
+0.87
-0.03
+0.04
+0.03
+1.01
+0.91
-0.04
-0.05
-0.03
+0.02
-0.02
R
S
R
S
S
S
R
R
S
S
S
S
S
0
22
0
26
23
27
0
15
28
18
26
20*
23
R
S
R
S
S
S
R
I
S
S
S
S
S
R
S
S
S
S
R
S
S
S
I
S
Usable Total = 12
Sample No 837, AQ = 5. 76 x 106, A2 5 = 5 58 x 107
HOO , 000 Staphylococcus coagulase megati
Penicillin
Ampicillm
Nafcillin
Cephalothin
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantoin
-0.08
-0.08
-0.10
-0.09
-0.01
+0.04
+0.03
+0 05
-0.03
+1.20
-0.00
-0.07
-0 02
S
S
S
S
S
S
S
S
S
R
S
S
S
28*
30*
26
42
25
30
30
40
39
0
32
24
29
S
S
S
S
S
S
S
S
S
R
S
S
S
R
R
S
S
S
S
S
R
S
I
S
Usable Total = 13
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results
Disagreement
Sample No 860, AQ = 4.49 106, A, g = 3.35 x 108
>100,000 Klebsiella
Penicillin
Ampicillin
Nafcillm
Cephalothin
Tetracychne
Chloramphenicol
Clmdamycin
Erythromycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantoin
+0 98
+1.12
+0 96
-0 00
+0 01
+0 01
+0.99
+0 95
-0 01
-0.01
-0 01
+1.00
+0 34
R
R
R
S
S
S
R
R
S
S
S
R
R
0
0
0
16*
18*
23
0
8
28
15
27
0
18
R
R
R
I
I
S
R
R
S
S
S
R
S
R
R
S
S
S
R
S
S
S
R
S
Usable Tot
(false R)
1 = 11
Sample No 883, AQ = 4 23 x 10 , A2 5 = 2.69 x 108
>100,000 E coll
Penicillin
Ampicillin
Nafcillin
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Cohstm
Kanamycin
Streptomycin
Nitrofurantoin
+1.01
-0 01
+1.03
-0 01
-0 01
+0.01
+0 01
+0.97
+0.66
-0.01
-0.01
-0.01
-0.01
-0 01
R
S
R
S
S
S
S
R
R
S
S
S
S
S
0
22
0
24
24
32 .
0
13
29
17.5
27
22
23
R
S
R
S
S
S
S
R
R
S
S
S
S
S
R
S
S
S
S
R
S
S
S
S
S
Usable Total = 13
Sample No. 898, AQ = 5.84 107, A = 1.43 x 109
>100,000 Enterococcus
Penicillin
Ampicillin
Nafcillin
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
Clindamycin
Erythromycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantoin
-0.02
-0.04
+1.05
+0.33
+0.01
+0.03
+0.04
+0 051
+0.03
+0.60
+0 94
+0 67
+0.88
+0.08
S
S
R
R
S
S
S
R
S
R
R
R
R
R
17
22
0
14
24
26
0
26
0*
0
0
0
23
I
S
R
R
R
S
S
R
S
R
R
R
R
S
I
S
R
S
S
R
S
R
R
R
S
(false S )
(false R)
Usable Total = 11
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results
Disagreement
Sample No. 012, A0 = 4 82 x 106, Ag g = 2 20 x 108
>100,000 £ co/i
Penicillin
Amptctllin
Cephalothin 160
Cephalothm 320
Tetracycline
Chloramphenicol
Clindamycin
Gentamicin
Cohstin
Kanamycm
Streptomycin
Nitrofurantoin
+0.87
-0.02
-0 01
-0.02
+0.04
+0.01
+0.70
-0.02
-0.02
-0.02
+0.01
-0.01
R
S
s
S
s
s
R
S
s
s
s
s
0
18*
19
19
20
21, 3
0
23
14
20
15*
20
R
S
S
S
s
! S
R
S
S
S
S
S
R
I
S
S
S
R
S
S
S
R
S
Usable Total = 11
Sample No. 046, AQ = 5 76 x 106, A2 5 = 2 20 x 108
>100,000 E coll
Penicillin
Ampicilhn
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
Clindamycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantoin
+1.23
+1.25
+0.03
-0.01
+1.21
+0.01
+0 03
-0.02
-0.02
-0.02
+ 1.09
-0 00
R
R
S
S
R
S
s
s
s
s
R
s
0
8
17*
17*
0
25
0
22
15
19
0
21
R
R
I
I
R
S
R
S
S
s
R
S
R
R
S
R
S
R
S
S
S
R
S
(false S)
Usable Total = 10
Sample No. 977, AO = 3.54 x 106, Ag 5 = 6 09 x 107
>100,000 Enterococcus
Penicillin
Ampicilhn
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
Clindamycin
Gentamicin
Colistm
Kanamycin
Streptomycin
Nitrofurantoin
-0.01
-0.05
+0.05
-0 03
+0.04
+0.04
+0.04
+0.73
+0 61
+0 81
+0 94
+0.04
s
s
s
s
s
s
s
R
R
R
R
S
17
22
13
27
22
0
13
0
0
0
27
I
s
R
S
S
R
S
R
R
R
S
I
S
R
S
S
R
S
R
R
R
S
(false S)
(false S)
(false R)
Usable Total = 10
* Disagreement
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Table 5-5 (Continued)
Antibiotic Index ATPInterpretation KB
K-B
Interpretation
Laboratory
Results Disagreement
Sample No. 524, AQ = 3 69 x 106, Ag 5 = 2 . 2 7 x 108
>100,000 E coll
Penicillin
Ampicillm
Cephalothin 160
Cephalothm 320
Tetracycline
Chloramphemcol
Clmdamycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantom
+1.08
-0 01
-0 01
-0.01
+0 01
+0 01
+0 89
-0.01
-0 02
-0.00
+0.07
-0.01
R
S
s
S
s
s
R
s
s
s
R
S
0
19
21
23
23
0
26
16
25
22
23
R
S
S
s
s
R
s
s
s
s
s
R
S
S
S
s
R
S
s
s
s
s
(false R)
Usable Total = 11i
Sample No. 588, Afl = 3 76 x 106, A2 g = 1 80 x 108
>100,000 Klebsiella
Penicillin
Ampicillm
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphemcol
Clmdamycin
Gentamicin
Cohstin
Kanamycin
Streptomycin
Nitrofurantom
+0.99
+0 99
-0.02
-0.02
+0.01
+0.02
+0.98
-0.02
-0.02
-0.02
+0.00
-0 01
R
R
S
s
s
s
R
S
s
s
s
s
0
0
23
23
29
0
24
13
22
19
21
R
R
S
s
s
R
S
s
s
s
s
R
R
S
S
s
R
S
s
s
I
Usable Total = 11i
Sample No. 662, A0 = 3 64 x 106, A2 g = 1.19 x lo8
>100,000 E coli
Penicillin
Ampicillin
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphemcol
Clmdamycin
Gentamicin
Cohstm
Kanamycin
Streptomycin
Nitrofurantoin
+1.20
-0.02
-0.01
-0.03
+0.04
+0.05
+1.61
-0.03
-0.03
-0.02
-0.01
-0.00
R
s
s
s
s
s
R
s
s
s
s
s
0
19
21
22
28
0
25
15
23
20
22
R
S
s
s
s
R
S
S
S
S
S
R
S
S
S
s
R
S
s
s
s
Usable Total = 11
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Table 5-5 (Continued)
Antibiotic Index ATP KBInterpretation
K-B
Interpretation
Laboratory
Results Disagreement
Sample No 861, A0 = 2 64 x 106, A2 5 = 1 74 x 108
>100,000 Emerobacler #1, >100,000 Enterobacter 12
Penicillin
Ampiclllln
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
CHndamycln
Gentamicin
Colistin
Kanamycln
Streptomycin
Nitrofurantoin
+1.02
+0.36
+0.11
+0.03
+0 01
+0 01
+0.85
-0.01
-0.01
-0.01
+0.00
-0 00
R
R
R
S
S
S
R
S
S
S
S
S
No. 1 No 2
0 0
13 13
13 13. 5
23 19
29 28
0 0
25 25
15 15
23 22
14,2022
19 18
No 1 No 2
R R
I I
R R
S S
S S
R R
S S
S S
S S
I S
S S
No 1 No 2
R R
S R
I R
S S
S S
R R
S S
S S
S S
S I
S S
(false S)
Usable Total = 10
Sample No. 878, AO = 5 83 x 106, A2 5 = 2.99 x 108
>100,000 Enterococcus
Penicillin
Amplcillln
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
Clindamycin
Gentamicin
Cohstin
Kanamycln
Streptomycin
Nitrofurantoin
+0.92
+0.98
+0.92
+0 94
+0.01
-0.01
+0.99
-0.02
-0.02
-0 02
-0.00
-0.01
R
R
R
R
S
S
R
S
S
S
S
S
0
0
0
23
29
0
26
15
23
20
21
R
R
R
S
S
R
S
S
S
S
S
R
R
R
S
S
R
S
S
S
S
S
Usable Total = 11
Sample No 927; A0 = 1.30 x 106, Ag = 1.21 x 107
30 - 50, 000 Staphylococcus with diptheroids
Penicillin
Ampicillin
Cephalothin 160
Cephalothin 320
Tetracycline
Chloramphenicol
Clindamycin
Gentamicin
Colistin
Kanamycin
Streptomycin
Nitrofurantoin
-0 04
-0.07
-0.04
-0.01
+0.10
+0.10
-0.01
+0.01
+0.76
+0.02
+0.31
-0.00
S
S
S
R
R
S
S
R
S
R
S
14
15
30
28
26
20
23
0
20
15
19
R
R
S
S
S
S
S
R
S
S
S
R
R
S
S
S
R
S
R
S
I
S
(false S)
(false S)
(false R)
(false R)
(false R)
Usable Total = 11
97
Table 5-6
Zone Diameter Criteria for Assigning Resistance or Sensitivity
Penicillin for Staphylococcus
for gram negatives
Ampicillin for Staphylococcus
for gram negatives
Nafcillin
Cephalothin
Tetraoycline
Chloramphenicol
Lincomycin (Clindamyoin)
Erythromyoin
Gentamicin
Cohstin
Kanamycin
Streptomycin
Nitrofurantoin
Sensitive
(disc size mm > )
29
22
29
14
14
18
19
18
15
18
13
11 .
18
15
17
Indeterminate Resistant
(disc size mm < )
20
11
20
11
9
14
14
12
10
13
12
8
13
11
14
There are certainly a number of factors that could give rise to disagreements between the
ATP method and Kirby-Bauer method, and some are listed as follows:
• Problems secondary to antibiotic mechanisms and expressed by prevalence of
certain organism-antibiotic combinations
• Inoculum size
• Limited growth of organisms over 2.5 hours
• Presence of white blood cells in the urine
• Clinical use of antibiotics
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Antibiotic Mechanism
Table 5-7 lists errors that occurred for each antibiotic tested. The sample number, organism
name, and number of organisms per ml by plate count are listed. Errors that occurred for
each sample are given across the page from left to right. False-resistant (R) or false-sensitive
(S) as defined previously are indicated along with the ATP index.
It is immediately apparent that a majority of errors occurred with ampicillm and cephalothm.
Considering only nonmixed samples, of 27 total errors, 6 occurred with ampicillm. All errors
were false-resistant. Two errors occurred with Proteus, three errors with E. coh, and one
error with Klebsiella Indices were in the low or middle range except for sample 524, which
had an index of 0.94.
The problem of false resistance with ampicillin-./^'otews had been identified in previous work
and was attributed to antibiotic mechanisms The reason for the problem with ampicilhn-
E coli combination is not clear.
Considering nonmixed specimens only, 6 of 27 total errors occurred with cephalothm Three
cases involved E. coh, two cases,Proteus, and one case, Enterococcus. All cases except
sample 977, Enterococcus, were false^esistant. The indices were in a low or middle range
in all cases of false-resistance. Some problems with the cephalothin-/>ofeus combination
had been observed in previous work, but an explanation for the cephalothin-£ coh combina-
tion problem is not clear.
Nitrofurantoin contributed 4 of 27 errors All except one were false-resistant with indices
in the low or middle range. Three of four errors occurred with the nitrofurantoin-A7efo/e//fl
combination
The remaining 10 errors were spread throughout the remaining antibiotics. The majority of
errors were again false-resistant.
Correlation for individual antibiotics, considering only nonmixed specimens, was as follows
Percent
Antibiotic Correlation
Penicillin 99.9
Ampicillin 82.4
Cephalothin 82.4
Tetracycline 97 0
Chloramphemcol 94 0
CUndamycm 94 3
Erythromycin 100 0
99
Percent
Antibiotic Correlation
Gentamicin 96.9
Colistin 100.0
Kanamycin 100.0
Streptomycin 88.9
Nitrofurantoin 88.2
Inoculum Size
Previous work had established that antibiotic susceptibility testing could be earned out suc-
cessfully with inoculum sizes of 1 X 10s or 1 X 106 organisms/ml. Inoculum sizes outside
this range might be a source of error. With these samples, the ATP level obtained from a
detection ATP assay (by the long centrifugation method) was used to dilute the bacterial
sediment in an attempt to achieve appropriate inoculum sizes. In all but three cases, the AQ
light units fell between 1 X 10s and 1 X 107 . In order to determine if inoculum size altered
correlation between the ATP method and the Kirby-Bauer, nonmixed samples were grouped
into four ranges according to light units • 1.0 X 105 to 1.0 X 106 ,1.0 X 106 to 5.0 X 106;
5.0 X 106 to 1.0 X 107 ; and > 1.0 X 107. Table 5-8 gives the results. For the three lower
ranges, correlations were not significantly different, 93.2, 92.9 and 95.8 percent. For the
three samples with AO'S > 1.0 X 107 , the correlation was lower at 85.7 percent. Because of
the limited number of samples involved, this does not prove that high A0's are a source of
error. Further clinical trials must attempt to clarify this problem.
Limited Growth of Organisms over 2.5 Hours
It had been observed earlier that when only a small amount of growth occurred in the growth
control, results did not correlate well with Kirby-Bauer. To test the influence of this factor
on results, samples were grouped as to the amount of growth that occurred in the growth
control. Table 5-9 gives these groupings. Fold increase in the fourth column was calculated
by dividing A2 s by AQ. Samples were grouped into three ranges as indicated: 0 to 30; 30
to 60; and 60-fold increase.
The group of samples in the 0 to 30-fold increase range did not have as high a correlation as
the higher ranges, 89.3 percent compared to 95.2 and 93.2 percent.
Presence of White Blood Celts in the Urine
The possibility that white blood cells in the urine might interfere with susceptibility tests
was of great concern. To examine this possibility, samples were grouped according to white
blood cell counts in the urine.
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Table 5-9
Analysis of Errors by Fold Increase (Nonmixed infection)
Specimen
Number
Organism
(Name and Number/ml)
Fold
Increase
Usable
Total Errors
% Agreement
with K-B
0 to 30. 0 fold increase
584
837
101
191
524
997
229
817
898
363
>100,000 Proteus
>100,000 Staphylococcus megati
XLOO.OOO Pseudomonas
>100,000 E coh
XLOO.OOO E coh
>100,000 Enterococcus
50-100, 000 Proteus
>100,000 E coh
>100, 000 Enterococcus
>100,000 P rettgeri
4.1
9.7
10.9
14.4
16.1
17.2
18.8
21.7
24.5
27.0
12
13
10
12
12
10
9
12
11
11
112
1
0
0
1
4
3
0
0
1
2
12 89.3%
30. 0 to 60. 0 fold increase
662
512
256
749
466
046
232
994
795
774
650
751
012
588
898
997
>100,000 E coh
>100, 000 E coh
>100, 000 Serratia marcesens
>100, 000 P rettgeri
>100,000 E coh
>100,000 E coh
XLOO.OOO Klebsiella
>100,000 E coh
>100,000 E coh
50-100,000 P rmrabihs
>100,000 E coh
>100,000 Klebsiella
>100,000 E coh
>100, 000 Klebsiella
>100, 000 Enterococcus
>100,000 E coh
32.7
34.3
36.8
37.1
37.7
38.2
38.9
39.5
39.8
40.0
43.6
43.8
45.6
47.9
51.3
53.1
11
12
12
13
12
10
12
13
13
12
11
12
11
11
11
13
189
0
1
0
2
1
2
0
0
0
1
1
1
0
0
0
0
9
.
95. 2%
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Table 5-9 (Continued)
Specimen
Number
Organism
(Name and Number/ml)
Fold
Increase
Usable
Total Errors
% Agreement
with K-B
>60.0 fold increase
524
883
361
294
860
504
200
946
>100, 000 E coli
>100, 000 E coli
>100,000 E coli
>100, 000 Klebsiella
XLOO, 000 Klebsiella
>100,000 E coh
>100,000 E coh
>100, 000 Klebsiella
61.5
63.6
70.8
73.4
74.6
76.4 .
112.0
121.1
11
11
9
12
11
12
11
11
88
1
0
2
1
1
0
0
1
6
,
/
QQ t)Q13O. £i /o
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Of interest is the distribution of white blood cell counts. Of 35 urines with nonmixed infec-
tions, only 5 had white blood cell (wbc) counts greater than 1 X 106/ml. The highest count
encountered was 3.0 X 106 wbc/ml. Thirteen of 35 urines had counts in the range of 1.0 X
10s - 1.0 X 106 wbc/ml. Seventeen of the 35 urines had less than 1.0 X 10s wbc/ml in the
urine.
Table 5-10 gives the specimen number, wbc/ml AQ light units for the sample, total antibiotic
determinations, and number of errors. Samples that had less than 1.0 X 10s wbc/ml had a
91.9-percent correlation with the Kirby-Bauer method. Samples with counts between 1.0
X 10s and 1.0 X 106 wbc/ml had a 94.7-percent correlation. Samples with Jcounts greater
than 1.0 X 106 wbc/ml had a 95.2-percent correlation. Certainly no trend towards decreas-
ing correlation with increasing white blood cell counts was found; in fact, the best results
were obtained with urines with the higher white blood cell counts.
To review briefly, the ATP susceptibility test relies on an increase in ATP over time. There-
fore, even if nonbacterial ATP falsely elevates the AO determination, it will elevate the A2 s
by the same increment. This constant contribution will usually become mathematically
insignificant when the ratio calculation is made. Secondly, significant pyurias are usually
accompanied by high bacteria counts. The sample will usually be diluted appropriately on
the basis of the ATP level obtained from the detection assay (long centrifugation) which can
handle at least 1.0 X 106 wbc/ml. When dilution is carried\out, the number of white blood
cells is proportionately reduced, and the contribution to the AQ decreases. This was con-
firmed in the clinical samples because high white blood cell counts did not result in higher
than normal AQ's.
Clinical Use of Antibiotics
In our preliminary work, using patient urine samples inoculated with various reference strains
of bacteria, clinical use of antibiotics, had interfered with susceptibility testing. This was
thought to be an artificial problem. If a patient developed a urinary tract infection while
on antibiotics, the organism would be resistant to the antibiotic in the urine. Growth would
occur in the growth control and susceptibility testing could be carried out.
We encountered four patients on antibiotics with significant bacteriurias. Sample numbers
978 and 994 (table 54) were from patients on ampicillin. Sample number 256 was from a
patient on gantrisin, and sample number 294 was from a patient on cephalothin. Only one
error occurred for 50 determinations from these samples giving a high correlation of 98.0
percent. Our impression that susceptibility testing can be carried out when the patient is
already on antibiotics was preliminarily confirmed.
In the study of clinical urine specimens, samples were selected that appeared by plate count
to contain only one organism. In seven samples a second organism was eventually recognized.
The samples were numbers 967, 040, 640, 739,978,168, and 927. In all except three
samples, the dominant organism was present at a level of greater than 100,000 organisms/ml,
and the second organism was present at a level of less than 10,000 organisms/ml. Sample
number 978 contained E coli at 50,000 to 100,000 organisms/ml and diptheroids at < 10,000
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Table 5-10
Errors According to White Blood Cell Countffln the Urine (Nonmixed)
Specimen Number
040
200
229
361
584
466
504
524
837
860
898
046
977
524
588
861
878
wbc/ml Light °Units UsableTotal Errors
<1.0 x 105
occasional
rare
rare
5. 0 x io4
3. 0 x 104
<104
0
7. 0 x IO4
occasional
7. 0 x IO4
5. 0 x IO4
occasional
1. 0 x io4
occasional
0
4. 0 x IO4
occasional
3.49x IO5
4. 50 x IO5
1. 60 x IO5
3.63 xlO5
6. 53
 x IO5
5.73 xlO6
3.69 xlO6
1.36
 X107
5.76 xlO6
4.49 xlO6
5.84 xlO7
5.76 xlO6
3.54 xlO6 '
3. 69 y IO6
3. 76 x IO6
2. 64 x IO6
5.83 xlO6
10
11
9
9
12
12
13
12
13
11
11
10
10
11
11
10
11
186
0
0
0
2
0
1
0
4
0
1
1
0
3
1
0
1
0
15
% Agreement
wrthK-B
91.9%
1.0 x 105- 1. 0 x 106
246
101
363
650
997
191
232
294
751
2.4 x IO5
1.0 x io5
1.0 x IO5
5. 1 x IO5
2.2 x IO5
1.0 x IO5
1. 5 x IO5
1.0 x IO5
1.2 x IO5
1. 90 x IO6
5.30 x IO5
5.07 xlO5
3.26 xlO 6
3.99 xlO5
4. 63 x IO6
8. 58 x IO6
5. 94 x IO6
9.87 x IO5
11
10
11
11
13
12
12
12
12
1
0
2
1.
0
1
0
1
1
107
Table 5-10 (Continued)
Specimen Number
774
817
883
662
wbc/ml
2.3
 x 105
6.6 x 105
3.4 x 105
7. 2
 x 105
AnLight °Units
8. 57 x 105
2.30 x 107
4.23 x 106
3. 64 x 106
Usable
Total
12
12
13
11
152
Errors
1
0
0
0
8
% Agreement
wffh K-B
94.7%
>1. 0 x 106
749
994
512
795
012
3.0 x 106
1. 2 x 106
1. 5 x 106
1.0 x 106
2.0 x lO 6
1. 93 x 106
9. 14 x 105
3.88 x 106
9.48 x 106
4.82 x 106
13
13
12
13
11
62
2
0
1
0
0
3 95. 2%
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organisms/ml. Sample number 739 contained 30,000 to 50,000 E. coli and < 10,000 Proteus.
Sample number 168 contained E. coli at > 100,000 organisms/ml and 30,000 to 50,000
P. mirabilis.
Agreement between the ATP method and the Kirby-Bauer method for these seven mixed
samples was 89.8 percent, which was only slightly lower than the overall agreement of 92.8
percent. It appears that susceptibility tests can be carried out with good correlation with
mixed infections when one organism greatly dominates the other.
SUMMARY
In summary, the clinical studies incorporating the changes outlined in this section established
that an ATP assay suitable for detection of bacteriurias could be combined successfully with
susceptibility testing, that results from an ATP assay suitable for detection of bacteriuria
could be used to establish appropriate bacterial inoculum sizes for susceptibility testing, and
that certain technical modifications representing considerable time and equipment savings
could be used without obvious decrease in correlation of results.
Our analysis of errors identified the following factors worthy of additional consideration:
• Particular antibiotics were responsible for the majority of errors (ampicillin and
cephalothin). The ampicillin-/Vo/ew5 combination was again recognized as a
source of false-resistant results. Future work should evaluate these problem
antibiotics, and possible solutions should be incorporated into further clinical-
trials. One hopeful possibility would be to lengthen the incubation period to 3
hours to solve the ampicillin problem.
• High AQ's may be a source of error and this factor should be examined with
further clinical trials.
• Mixed cultures gave workable results in this study when one organism dominated.
Future work must evaluate mixed cultures in which more equal numbers of two
organisms are found., (Shahidi, Ellner, 1969)
• White blood cells in the urines did not interfere with the ATP antibiotics suscep-
tibility testing at levels encountered in this clinical trial. Urines with higher white
blood cell counts should be sought and evaluated.
Concerning overall success of the method, the 92.5-percent correlation for all samples is in
agreement with that obtained by Vellend in the pure species work. It is confirmed that the
ATP antibiotic susceptibility testing methods can be applied directly to urine specimens.
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INTRODUCTION
Optimum use of antimicrobial agents to treat infection depends upon knowledge of the sus-
ceptibility of the infecting organism. Although susceptibility can sometimes be predicted
from the general behavior of the bacterial species involved, the most reliable approach is
generally that of direct measurement of the in vitro interaction between the organism and
the drug.
Present techniques of microbial sensitivity testing generally require overnight incubation
after primary isolation of the infecting organism This requires a minimum of 48 hours after
the specimen is received in the laboratory. The methods most widely used are agar diffusion
(Kirby-Bauer), broth dilution, and agar dilution. Only the agar diffusion technique is rea-
sonably well standardized and is widely used in clinical microbiology laboratories. This delay
in providing the physician with accurate susceptibility data often results in the institution of
empirical and/or broad-spectrum antimicrobial therapy in urgent clinical situations. The
in vivo patient response to this therapy can often be measured before the laboratory is able
to provide in vitro sensitivity data. The availability of a rapid method of testing bacterial
susceptibility would permit prompt selection of the most effective agent and therefore avoid
the inclusion of inappropriate, unnecessary, and often toxic agents in the initial therapeutic
regimen.
Several rapid methods of microbial susceptibility testing, incorporating a wide variety of
techniques of measuring antimicrobial effect, have been described in the past few years. We
have chosen to measure ATP as an indicator of antibiotic effect for several reasons: (1) this
substance is present in all viable microorganisms; (2) its concentration in bacteria is directly
related to fundamental processes of oxidative phosphorylation and respiration; (3) although
none of the commonly used antimicrobial agents acts directly on oxidative phosphorylation
and respiration, it is evident that they may have profound indirect consequences on the ATP
content of bacteria; and (4) the measurement of ATP by the luciferase bioluminescence
reaction is precise, reproducible, and compatible with automation. The assay can be made
specific for bacterial ATP by chemically removing the ATP associated with nonbacterial cells
as well as any soluble ATP. This is accomplished by treating the specimen with a nonionic
detergent, Triton X-100. Under the conditions used in our experiments, this detergent se-
lectively lyses mammalian cells without effecting any change in the ATP content of bacteria.
An ATPase is then added which hydrolyzes all the free ATP. An individual specimen can be
assayed for its ATP content by this method in less than 30 minutes.
In conventional methods of testing susceptibility to antimicrobial agents, the end-point is
measured after 18 to 24 hours of interaction between drug and microorganism. Any method
which attempts to assess this interaction at a shorter interval offers the distinct possibility
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that results may differ from those obtained by the longer method. The majority of the
discrepancies will arise from three factors: (1) the particular characteristic of the bacterium
being measured; in this case, bacterial ATP; (2) the mode of action of the antimicrobial agent;
and (3) the mechanism of resistance to the antimicrobial agent.
MATERIALS AND METHODS
Bacterial Strains
The majority of the bacterial strains used in this study were clinical isolates obtained from
the diagnostic microbiology laboratory at the New England Medical Center Hospital. Ref-
erence strains were obtained from the American Type Culture Collection (Escherichia coli
ATCC 25922 and Staphy loco ecus aureus ATCC 25923) and from Difco Laboratories Bac-
trol Discs (Klebsiella aerogenes ATCC 23351,Enterobacter cloacae ATCC 23355,Serratia
marcescens ATCC 8100, Proteus vulgaris ATCC 6380,Pseudomonasaeruginosa ATCC
14207). Each strain was characterized by standard laboratory techniques. The following
number of strains of each species were studied: Escherichia coli (11), Klebsiella aerogenes
(10), Enterobacter cloacae (6), Serratia marcescens (6),Proteus mirabilis (11),Proteus
vulgaris (2), Providencia stuartii (1), Pseudomonas aeruginosa (11), Staphylococcus aureus
(18), Staphy loco ecus epidermidis (2), and Enterococcus (11).
These organisms were maintained on trypticase soy. agar slants at 4°C. At monthly intervals,
a fresh broth culture was streaked out on 5-percent sheep's blood agar and eosinmethylene
blue agar to confirm purity. Five similar colonies from the blood agar were inoculated into
fresh broth from which new agar slants were prepared. Agar diffusion sensitivity tests were
done periodically on these strains to confirm stability of their susceptibility patterns.
Antibiotics
Standard antibiotic powders suitable for sensitivity testing were obtained'from manufacturers:
Bristol Laboratories, Syracuse, New York—ampicillin trihydrate and tetracycline hydrochlo-
ride; Eh Lilly and Company, Indianapolis, Indiana—potassium penicillin G, sodium cephalo-
thin and erythromycin base; Warner-Chilcott Laboratories, Morris Plains, New Jersey—sodium
cohstimethate; Eaton Laboratories, Norwich, New York—nitrofurantoin; Wyeth Laboratories,
Philadelphia, Pennsylvania-sodium nafcillin and sodium ampicillin, Win throp Laboratories,
New York, New York—nalidixic acid; Parke, Davis and Company, Detroit, Michigan—chlor-
amphenicol; Roerig, New York, New York—disodium carbenicillin^ Schering Corporation,
Bloomfield, New Jersey—gentamicin sulfate; Upjohn Company, Kalamazoo, Michigan—clinda-
mycin phosphate; Hoffmann-LaRoche Inc., Nutley, New Jersey—sulfisoxazole. All standard
powders were stored in a vacuum desiccator at 4°C.
To prepare stock solutions (1280 jug/ml), these powders were dissolved in sterile distilled
water and dispensed into sterile, capped polypropylene tubes (12 X 75 mm) using a Cornwall
syringe pipette with a 0.22-/zm Millipore filter. Special solvents were used in small amounts
for sulfisoxazole (10-percent sodium hydoxide), erythromycin base (ethanol), nitrofurantoin
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(dimethylformamide, as per manufacturers'instructions), and nalidixic acid (IN sodium hy-
droxide). These solutions were frozen at -20°C for no longer than 2 weeks and used within
1 hour of being thawed.
The antibiotics studied and the concentration used to determine ATP index are|shown in
table A-l. The concentration selected was determined empirically by measuring the effect
of the mean inhibitory concentration (MIC) breakpoints generally quoted for the agar dif-
fusion method on a panel of prototype organisms. The concentrations shown in table A-l
fall somewhere in between these MIC breakpoints.
Table A-l
Comparison of Results Obtained by the ATP
Index and Agar Diffusion Sensitivity Testing
Antibiotic
Ampicillm
Penicillin G
Nafclllln
Carbeniclllin
Cephalothin
Tetracycline
Erythromycin
Clindamycin
Gentamicin
Nitrofurantoin
Colistm
Chloramphemcol
Concentration
WJ/ml
8
8
0.075*
0.6
128
16
6
4
2
6
50
8
12.5
TOTAL
Total
Strains
69
69
18
2
33
82
81
77
78
81
83
81
81
835
DISAGREEMENT
Total
13
10 •
1
0
7
4
7
4
9
0
19
2
7
83
(%)
(19)
(14)
(5)
(0)
(21)
(5)
(9)
(5)
(12)
(0)
(23)
(2)
(9)
(10)
Major
13
10
1
0
4
4
2
0
9
0
13
2
5
63
False
Resistant
12
10
1
0
4
3
1
0
0
0
12
0
3
46
Sensitive
1
0
0
0
0
1
1
0
9
0
1
2
2
17
Minor
0
0
0
0
3
0
5
4
0
0
6
0
2
20
"S aureus strains only.
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Agar Diffusion Sensitivity Testing
Agar diffusion sensitivity testing was performed according to the tentative standards recom-
mended by the National Committee for Clinical Laboratory Standards Subcommittee on
Antimicrobial Susceptibility Testing.
Broth Dilution MIC's
This procedure was done in trypticase soy broth according to the method proposed by the
International Collaborative Study on Antibiotic Sensitivity Testing.
ATP Index
Method of Incubation
A fresh overnight broth culture is diluted 1000-fold in trypticase soy broth at 37°C to obtain
an inoculum of approximately 106 colony-forming units (cfu)/ml. This is preincubated for
30 minutes at 37°C and 4.5 ml was added to each of two tubes, tube A containing 0.5 ml of
sterile 0.9-percent sodium chloride (growth control), and tube B containing 0.5 ml of an
antibiotic solution in 0.9-percent sodium chloride to yield the final concentration shown in
table A-l. From control tube, A, 0.5 ml of the broth culture is immediately assayed for ATP
(A0), and both tubes are incubated at 37°C for 2.5 hours; 0.5-ml samples from each tube are
then assayed for ATP (At and Bt).
Method of A TP Assay for Pure Bacterial Species in Broth
Because small amounts of ATP are ubiquitous in untreated water, it is necessary to use dis-
tilled, deionized water in preparing all reagents. ATP clings to glassware, therefore all glass-
ware must be acid cleaned. Plastic ware is generally preferable. Many commercial detergents
will interfere with the assay, and glassware must be scrupulously free of residue.
Two basic reagents are used:
• Apy-Ca-Tx-A solution of 0.03 M calcium chloride and 0.6^>ercent Triton X-100
is kept frozen at -20°C in aliquots suitable for a day's work. Five mg ATPase
(Apyrase, Grade 1, Sigma) per ml are added to this solution immediately prior to
performance of the assay and gently mixed by inversion.
• Luciferase—The contents of one vial of luciferase (Luminescence Biometer Reagent
Kit, DuPont Instruments) are reconstituted with 1.5 ml of 0.2 M TRIS (Trizma
base, Sigma) containing 0.01 M magnesium sulfate (pH 8.4), which is also kept
frozen in suitable aliquots. After complete solution, the reagent is dispensed
(0.1 ml) into reaction cuvettes (6 X 50 mm).
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The assay is performed in the following steps:
1. Place a 0.5-ml sample of the broth culture in a sterile polypropylene tube (17 X
100mm).
2. Add 0.1 ml of Apy-Ca-Tx. Vortex well and wait 15 minutes.
3. Add exactly 0.1 ml of 1.5 N nitnc acid. Vortex tube and allow to stand for 5
minutes.
4. Add 4.3 ml of sterile, deionized water (Travenol, sterile water for irrigation) and
mix well.
5. Draw 0.1 ml of the reaction mixture into a disposable tuberculin syringe and
inject into the luciferase,'reagent.
6. Readings are made in a photometer (DuPont Luminescence 760 Biometer) stand-
ardized to 1.00 X 108 femtograms (fg) ATP/ml of original sample by adding 0.05
ml of a freshly thawed ATP standard (1.0 /ug/ml) to the final reaction volume of
a blank tube (sterile broth).
Calculation of ATP Index
The drug effect on bacterial ATP content was quantitated using the following formula:
log Bt - log A0
ATP Index =
log At - log AQ
the current interpretation of the ATP index is as follows:
>+ 0.25 Resistant
<+ 025 Sensitive
Reproducibility Studies
A limited study was undertaken to determine the reproducibility of the ATP index. The same
10 bacterial cultures (E. coli ATCC 25922, Klebsiella Pneumoniae ATCC 23357, Enterobacter
cloacae ATCC 23355, Serratia marcescens ATCC 8100, Proteus vulgaris ATCC 6380 and
NEMCH 528, Pseudomonas aeruginosa ATCC 14207, Providencia stuartii NEMCH 321,Staph-
\ylococcusaureus ATCC 25923, and Staphylococcus epidermidis ATCC 12228) were tested '
independently by two different technologists using different batches of reagents and anti-
biotics. The same instrument was used for the ATP assay.
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Effect of Varying Inoculum Size on Microbial Sensitivity Testing by the ATP Index
The effect of varying the initial bacterial inoculum size, namely 5 X 104 cfu/ml and 5 X 107
cfu/ml, was studied and compared to the standard inoculum (1 X 106 cfu/ml). In order to
perform the ATP assay with the smallest inoculum (5 X 104 cfu/ml), the procedure was
modified as follows to give the increased sensitivity required.
1. Place a i5.0-mllsample of the broth culture in a sterile polypropylene tube (17 X
100mm).
2. Add 1.0 ml of Apy-Ca-Tx (10 mg apyrase/ml) and vortex.
3. Centrifuge tube for 15 minutes at 10,400 RCF X G at 20°C.
4. Decant and invert on filter paper for 5 minutes.
5. Add 0.2 ml of 0.0625 N nitric acid to the precipitate. Vortex and allow to stand
for 5 minutes.
6. Add 0.2 ml of sterile, deionized water, and vortex.
7. Assay 0.1 ml of this reaction mixture.as in the previous method, except the photo-
meter is standardized to 1.0 X 108 fg/ml of original sample by adding 0.05 ml
of a freshly-thawed ATP standard (0.1 Mg/ml) to the final reaction volume of a
blank tube (sterile broth).
|3-Lactamase Activity
The j3-lactamase activity of the S. aureus strains tested was determined by the procedure of
Foley and Ferret.
RESULTS
An overall comparison of the results obtained by the ATP index and agar diffusion sensitivity
testing is shown in table A-l. Of the 83 (10 percent) instances of disagreement, most (75
percent) were major, that is, false-resistance (46 of 63) or false-sensitivity (17 of 63). One-
quarter of the disagreements were minor, that is intermediate by agar diffusion and either
sensitive (11 of 20) or resistant (9 of 20) by the ATP index. The reasons for disagreement
were studied in detail.
Agreement by Antibiotic
Ampicillin
Twelve of the 13 disagreements were with Proteus species (mainly P. mirabilis) which ap-
peared falsely resistant to this antibiotic. The reason for this discrepancy is shown in figure
A-l. The fall in bacterial ATP content which coincides with lysis of the organism by ampi-
cillin (a cell wall-active or |34actam-antibiotic) takes at least 3 hours after exposure to the
drug, and earlier determination of drug-effect would predictably show false resistance.
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Figure A-1 Change in bacterial ATP when P. mirabilis (9 strains)
were grown in the presence of ampicillin (8 ^ g/ml in TSB).
The 10 strains that were in disagreement were confined to P mirabilis, which appeared falsely-
resistant to this antibiotic. This discrepancy is due to a similar delay in the lysis of P. mirabilis
strains by penicillin G as was demonstrated for ampicillin.
The determination of S. aureus susceptibility to penicillin G presents unique difficulties.
Penicillinase-producmg S. aureus frequently appears sensitive to penicillin at 8 jug/ml after only
a few hours of growth because there is insufficient time for penicillinase induction to take
place. This problem can partly be overcome by using a much lower concentration of penicillin
G, such as 0.075 Mg/ml, which gives agreement in 17 of 18 instances,(table A-2).
Carbenicillin
Only E. coli, Proteus, and P. aeruginosa strains were studied for susceptibility to this drug
because these are the only genera for which interpretive zone standards are available. False-
resistance was a frequent problem with Pseudomonas strains. This discrepancy is due to the
fact that lysis of most Pseudomonas strains by carbenicillin takes longer than 6 hours (figure
A-2).
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Table A-2
Comparison of S. aureus Sensitivity to Penicillin G by Agar
Diffusion, Penicillinase Production, and the ATP Index at
Varying Concentrations of Penicillin
Strain
ATCC 25923.
091
315
352
511
280
187
917
752
972
801
593
896
697
565
563
581
580
Agar
Diffusion
Zone Diameter
32.5
40
37
38.5
37
43
18
18.5
20
19
17
18
22
24.5
25
24
23
26.5
Interpretation
S
S
S
S
S
S
R
R
R
R
R
R
I
I
I
I
I
I
Penicillinase
Production
-
-
-
-
-
-
+
+
+
+
+
+
+
+
+
+
+
+
ATP Index
Penicillin G
0.05 g
40.29
0.00
+0.12
+0.22
+0.58
+0.31
+0.70
+1.00
+0.66
+0.94
+0.99
+0.99
+0.87
+0.60
+0.49
+0.36
+0.84
+0.71
INT
R
S
S
S
R
R
R
R
R
R
R
R
R
R
R
R
R
R
0.075
+0.04
-0.13
0.01
+0.14
+0.57
+0.19
+0 85
+1.00
+0.53
+0.99
+0.94
+0.98
+0.62
+0.29
+0.38
+0.33
+0.71
+0.69
INT
S
S
S
S
R
S
R'
R
R
R
R
R
R
R
R
R
R
R
0.10
+0.08
-0.22
+0.02
+0.07
+0.42
+0.05
+0.40
+0.92
+JX28
+0.24
+0.93
+0.92
+0.75
+0.14
+0.04
+0.07
+0.45
+0.28
INT
S
S
S
S
R
S
R
R
R
R
R
R
R
S
S
S
R
R
Cephalothin
There were only four discrepancies with this drug, three instances of false^esistance with P.
mirabilis, again reflecting the delayed time-to-lysis of these strains by cell wall-active 0-lactam-
antibiotics. The one instance of false sensitivity of an Enterobacter strain illustrates the un-
common instance, where, despite an apparent zone of inhibition in the susceptible'range by
agar diffusion, several colonies are seen within the zone. Provided purity of strain can be
confirmed, this must be interpreted as resistance, a fact confirmed by MIC determinations.
A rapid susceptibility technique is likely to report these as falsely-sensitive, because the majority
of the bacterial population in the inoculum is, in fact, susceptible to the drug.
Tetracycline
There were seven disagreements, but only two of these were major with no particular pattern.
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Figure A-2 Change in bacterial ATP when Pseudomonas were
grown in the presence of Carbentcillm (128 ns/m\).
Erythromycin
There were no major disagreements with this antibiotic. The four minor disagreements were
confined to enterococci which were sensitive by the ATP index and intermediate by disc.
Clindamycin
All nine instances of disagreement were with enterococci that were sensitive by the ATP
index and resistant by disc. The reason for this discrepancy is shown on figure A-3. Con-
siderably subinhibitory concentrations (that is, much less than the MIC) of clindamycin in-
hibit ATP synthesis during the first two hours, but thereafter ATP synthesis (and bacterial
multiplication) precedes at a rate similar to that of the control. Thus, there is an apparent
lag before the ultimate resistance of the organism becomes apparent.
Gentamicin
There was complete agreement between the two methods with this aminoglycoside antibiotic.
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Figure A-3. Change in bacterial ATP when enterococcus (10 strains)
were grown in the presence of clindamycin (2 Mg/ml).
Nitrofurantoin
There were 19 disagreements, 6 minor and 13 major. Twelve of the major disagreements
were instances of false-resistance to nitrofurantoin; by staphylococci and enterococci. The
ATP index in all these instances was very close to the breakpoint value of +0.25. When this
problem was studied in more detail (figure A-4), the inhibition of S. aureus by nitrofurantoin
was not apparent until after 1 hour of incubation. Due to the relatively slower growth of the
control organism in comparison to gram negative organisms, the requisite index for sensitivity
cannot quite be achieved even in 3 hours. This problem could be solved by applying a dif-
ferent interpretive criteria to this drug, namely a breakpoint ATP index of +0.35.
Colistin
There were only two disagreements, both instances of false-sensitivity to Enterobacter-Serratia
strains. These again were instances where there was an apparent zone of inhibition in the sen-
sitive range by agar diffusion, but several colonies were seen within the zone, necessitating an
interpretation of resistance.
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Figure A-4. Change in bacterial ATP when S. aureus (10 strains) were
grown in the presence of nitrofurantoin (50 p.g/m\).
Chloramphenicol
There were seven discrepancies with this antibiotic (five major, two minor) distributed among
several species with no particular pattern of disagreement.
Sulfisoxazole
Rapid sensitivity testing to this agent appears impossible by this technique. The ATP index
consistently gave false^esistant results. As shown in figure A-5, there was no sulfonamide
effect measurable after 3 hours of log phase growth using an initial inoculum of 5 X 104
cfu/ml.
Nalidixic Acid
The ATP index consistently gives false-resistant results with this agent as well (figure A-6).
Reproducibility Studies
Table A-3 summarizes the results from each technologist. Each one achieved the same degree
of overall agreement with the agar diffusion method. This agreement was similar to that
achieved by the ATP index in general (90 percent). There is a 94-percent agreement between
the technologists.
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Table A-3
Reproducibility of the ATP Index When
Performed by Different Technologists
Antibiotic
Ampicillin
Penicillin G
C arbenicillin
Cephalothin
Tetracycline
Erythromycin
Clindamycin
Gentamicin
Nitrofurantoin
Colistin
Chloramphemcol
TOTAL
No.
Strains
Tested
8
8
4
10
10
10
10
10
10
10
10
100
Major disagreements with
Agar Diffusion
Tech-1
2
0
0
0
0
0
0
1
2
1
2
8
Tech-2
3
0
0
0
0
0
0
0
2
0
3
8
Disagreements Between
Tech-1 and Tech-2
1
0
0
0
1
0
0
1
1
1
1
6
Effect of Varying Inoculum Size
Although there was considerable variation in the absolute value of the ATP index (especially
when negative values were obtained), there was 100-percent correlation with the standard
1 X 106 cfu/ml inoculum when an inoculum of 5 X 104 cfu/ml was used. Valid data could
not be obtained for the S. aureus strain used (ATCC 25923) because there was no significant
increment in the ATP content of the control organism during the 2.5-hour period of incuba-
tion. Using an inoculum of 5 X 107 cfu/ml, there were five instances of disagreement with
the method using the standard inoculum: the K. aerogenes and P. mirabilis strains resistant
to nitrofurantoin appear falsely-sensitive to this drug; and the E. coli and Klebsiella strains
sensitive to colistin appear falsely-resistant. Valid data could not be obtained for the P. aer-
uginosa strain used because there was no significant increment in the ATP content of the
control organism during the 2.54iour period of incubation.
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DISCUSSION
The system for determining microbial susceptibility to antibiotics that we have developed
using the luciferase assay for ATP gives a 90^>ercent correlation with existing rapid methods
that have undergone extensive laboratory evaluation.
The 2.5 hours of incubation required to achieve the 90-percenticorrelation seem to be the
minimum duration necessary for adequate multiplication of the.control organism (three to
five doubling times) and to demonstrate drug effect at concentrations commonly achieved
in clinical practice. Extending the incubation period by 1 hour would clearly improve the
correlation (for example, /Hactam 'antibiotics against P. mirabilis). There are infrequent
instances where the increment in bacterial ATP during the usual incubation period is insuf-
ficient to allow any valid conclusions to be drawn about antibiotic effect'. At the standard
inoculum size, this problem is virtually limited to 5. aureus strains. Due to its infrequent
occurrence, we have not yet evaluated the effect of adding 0.2 percent KNO3 to the medium.
The inoculum size for most microbial susceptibility tests is carefully standardized, particularly
for the agar-d if fusion method. Although we have used a standard inoculum of 1 X 106 cfu/
ml, evaluation of a smaller inoculum (5 X 104 cfu/ml) gives equally good results except for
the failure of the S. aureus strain tested to demonstrate a significant increment in ATP con-
tent during the incubation period of the control. Less reproducible results were obtained
with the larger inoculum of 5 X 107 cfu/ml.
The interpretive criteria that has been tentatively adopted for the ATP index may yet be
subject to modification as further experience is gained with this method. It may not be fea-
sible to establish a single ATP index for all antimicrobials, as has already been noted with
nitrofurantoin. We are unable at this time to define an "intermediate" category of sensitivity.
The major cause for disagreement between the ATP index and agar diffusion is the mode of
action of the antimicrobial agent. This is particularly evident of cell wall-active /3-lactam-
antibiotics on grarrmegative bacteria, where one-half of all the major disagreements were
seen, including all instances of false^esistance. When a /J-lactam-antibiotic is added to a sen-
sitive gram-negative bacterium in the logarithmic phase of growth, the bacterium undergoes
a series of morphological changes from filamentous to bulbous or "bow-tie"(forms to sphe-
roblasts before finally undergoing osmotic lysis. These changes are related to drug-induced
alterations in the cell-wall structure and may be dependent on the relative inhibitory effect
of j3-lactam antibiotics on two different enzymes: an endopeptidase concerned with cell
division and a glycosidase concerned with cell growth. The rate at which these changes occur
are dependent on the specific drug, on its concentration, on the type and rate of production
of/3-lactamase by the bacterium, and on the stability of the drug to |3-lactamase. In addition,
the time to lysis is dependent on the osmolality of the medium (being more rapid at lower
osmolalities) and the osmotic susceptibility of the species with damaged cell walls (JE. coli
being more susceptible than P. mirabilis) (Greenwood and O'Grady, 1969). Continuous tur-
bidometric recordings of these events show increasing opacification of the broth cultures
(indicating increasing bacterial cell mass despite absence of cell division) for varying lengths
' of time after the addition of the drug until lysis occurs, ficterial protein synthesis is not
inhibited by this class of drugs.
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When bacterial ATP content is used as a measure of |3-lactam antibiotic effect on log phase
cultures, the drop in ATP (indicating sensitivity) occurs at the time of lysis. A prolonged
time to achieve lysis was seen with penicillin G and ampicillin against P. mirabihs (figure
A-l) and carbemcillin against P aeruginosa (figure A-2). These findings are consistent withl
those of other investigators using a turbidometric index of cell lysis. This phenomenon may
make it necessary to extend the minimum period of incubation to one which will encompass
the time to lysis of such commonly encountered species as P. mirabilis.
Sulfonamides act as competitive inhibitors of p-amino benzoic acid in the biosynthetic reac-
tion to form dihydrofolate in bacteria. In vitro sensitivity to sulfonamides has always pre-
sented special difficulties because of: (1) the presence in many microbiological media of
substances that inhibit the antibacterial action of sulfonomides (this can be neutralized by
the addition of lysed horse blood) and (2) the necessity of using a very small inoculum of
organisms since bacteria must undergo many generations before any drug effect becomes
apparent. The latter point effectively precludes 'rapid' measurement of drug effect; as would
be expected, the ATP index consistently gave false-resistant results (figure A-5).
The ATP index consistently gave false^esistant results with nalidixic acid (figure A-6). This
was not surprising in view of the fact that nalidixic acid is known to exert its antibacterial
effect primarily by interfering with synthesis of deoxyribonucleic acid (DNA). Formation
of ribonucleic acid (RNA), protein, and lipid are relatively undisturbed so that synthesis of
ATP precedes for a substantial period of time. Nalidixic acid has little or no effect on respi-
ration with glucose as substrate.
The major advantage of the ATP system is that the assay can be made specific for bacterial
ATP. Both the Technicon Automated Antibiotic Susceptibility (TAAS) System and the
Autobac ltm system use an optical cell counting instrument that necessitates the use of spe-
cially prepared "optically clean" liquid media. Our laboratory is currently developing a meth-
od by which rapid antimicrobial susceptibility can be applied directly to organisms in urine
without prior bacterial isolation or subculture. This application requires a technique of meas-
uring bacterial growth that is specific for bacteria and not interfered with by particular matter
that is found in biological fluids such as urine.
The procedure described is compatible with automation since automated systems will be nec-
essary to perform the large number of assays involved.
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APPENDIX B
PROCEDURE AND EXPERIMENTS
PROCEDURE 1: SCREENING-LONG CEIMTRIFUGATION
1. ! Centrifuge a .35-ml urine sample at 8,000 RCF X G for 15 minutes at 4°C. |
2. Reconstitute pellet with 1.75 ml TSB.
Vortex.
Pipette 0.5 ml into a 17-x 100-mm polypropylene tube.
Store remaining 1.25 ml in refrigerator.
3. Add 1.0 ml apyrase (10 mg/ml 0.03 M CaCl2 -0.6 percent TX) to 0.5 ml reconstituted
urine sample.
Vortex.
Add 4.5 ml 0.9 percent N saline.
Add 0.02 ml 6.0 percent TX.
Vortex.
'Wait 15 minutes.)
4. Add 1.0 ml 0.25 M malic acid.
Vortex.
5. Centrifuge at 8,000 RCF X G for 15 minutes at 4°C.
Invert and drain for 5 minutes. '
6. Add 0.2 ml 0.1 NHNO3 .
Vortex.
Wait 5 minutes. 1
7. Add 0.2 ml sterile distilled H2 O.
Vortex.
8. Inject 0.1 ml sample into 0.1 ml luciferase (prepared one hour before by adding 1.5 ml
0.25 M TRIS, 0.01 M MgSO4, pH 8.2, to one vial of DuPont luciferase powder).
Read biometer for ATP light units.
PROCEDURE 2: DETERMINATION OF ANTIBIOTIC SENSITIVITIES
Nonconcentrated Procedure Without Malic Acid
1. Retrieve 1.25 ml sample from refrigerator.
Dilute with TSB to achieve appropriate ATP level.
2. Preincubate 0.5 hour at 37°C.
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3. Set up 17-x 100-mm polypropylene tubes to contain as follows:
A0 = 0.45 ml sample+0.05 ml sterile distilled H2O
A^. = 0.45 ml sample+0.05 ml sterile distilled H2O
B140 = 0.45 ml sample +0.05 ml antibiotic (aliquots previously frozen in tubes
and brought to room temperature)
A0 = 0.40 ml sample+0.1 Oml TSB
A2S = 0.40 ml sample+0.1 Oml TSB
Bn = 0.40ml sample+0.10 ml nitrofurantoin
4. | Incubate all except the AQ 's at 37°C for 2.5 hours. !
5. Add 0.1 ml apyrase (that remaining from Procedure 1) to AO 's.
Vortex.
Wait 15 minutes.',
6. Add 0.1 ml 1.5 N HNO3 to AQ 's.
Vortex. '
Wait 5 minutes. 1
7. Add 4.3 ml sterile distilled H2 O to AO 's.
Vortex.
Hold at room temperature.
8. At end of 2.5-hour incubation period, remove tubes from incubator.
Add 0.1 ml apyrase (10 mg/ml 0.03 M CaQ2-0.6 percent TX, prepared anew).
Vortex.
Wait 5 minutes. |
9. AddO.l ml 1,.5NHNO3.
Vortex.
Wait 15 minutes.
10. Add 4.3 ml sterile distilled H2 O.
11. Assay all tubes by injecting a 0.1 -ml sample (mixing sample with syringe) into 0.1
ml luciferase (prepared one hour before by adding 1.5 ml 0.25 M TRIS, 0.01 M MgSO4,
pH 8.2, to one vial of DuPont luciferase powder).
Read biometer for ATP light units.
EXPERIMENT 1: STABILITY OF THE A,, WITH E. COLI
Purpose
In order to determine antibiotic sensitivities at the end of a 2.5^iour incubation period, the
level of ATP at time zero must be established. Consistency and a more efficient use of lucif-
erase would be achieved if the AQ could be assayed 2.5 hours later with those samples con-
taining antibiotic. The purpose of this experiment was to determine how to store the A0
during the given incubation period so that the level of ATP would not change significantly.
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Procedure
1. Inoculate 20 ml of urine with an overnight growth of E. coli in TSB to achieve 107
organisms/ml. ~
2. ! Centrifuge at 8,000 RCF X G for 15 minutes at 4°C. !
3. Reconstitute pellet in 20 ml TSB.
4. Preincubate for 0.5 hour at 37°C.
5. Pipette 0.5-ml aliquots of infected broth into 7 tubes and prepare each as follows:
a. Refrigerate Uj for 2.5 hours. !
, b. Hold U2 at room temperature for 2.5 hours.
c. Incubate U3 at 37°C for 2.5 hours.
d. Extract ATP from bacteria in U4, U5, and U6, first by adding 0.1 ml 10 mg
apyrase/ml 0.03 M CaCl2 - 0.6 percent TX (vortex and wait 15 min. for hydroly-
sis of soluble ATP), then adding 0.1 ml 1,5 N HNO3 (vortex and wait |5 minutes. I
for extraction of bacterial ATP), and finally diluting with 4.3 ml H2 O (vortex):
1. Freeze U4 for 2.5 hours.
2. Refrigerate Us for 2.5 hours, j
3. Hold Ufi at room temperature for 2.5 hours.
e. Extract ATP from bacteria in the seventh sample and from 0.5 ml of TSB (as
described above), and assay by injecting 0.1 ml final processed sample into 0.1
ml luciferase in 0.25 M TRIS, 0.01 M MgSO4, pH 8.2. These samples will serve
as the A0 and the blank (Uconttol).
6. At the end of the 2.5-hour period, bring all samples to room temperature, extract '
bacterial ATP (as described above) in Uj, U2, U3, and assay Uj, U2, U3, U4, Us,
and U6 by injecting into luciferase.
The results of this experiment are shown in table B-l.
Conclusions
If the AQ, containing intact bacteria, is stored at room temperature or 37°C, for 2.5 hours,
bacterial ATP increases significantly. Refrigeration seems to kill a small proportion of the
organisms (or to decrease their ATP content).
If the bacteria are lysed by the addition of HNO3 and the sample is diluted before storing,
no change in the ATP level occurs whether the sample is stored in the freezer, refrigerator,
or left at room temperature. This conclusion is restricted to a 2.5-hour storage period of the
A0 and to a urine inoculated with E. coli.
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Table B-l
Results of Various Treatments of Sample before Assay
Sample Treatment Before Assay Light Units
control assayed immediately
assayed immediately
refrigerated, extracted, diluted
room temperature, extracted, diluted
37°C, extracted, diluted
extracted, diluted, frozen
extracted, diluted, refrigerated
extracted, diluted, room temperature
2.94 X 10s
4.50 X 107
3.67 X 107
3.03 X 108
8.86 X 108
4.55 X 107
4.51 X 107
4.58 X 107
EXPERIMENT 2: STABILITY OF THE AQ WITH OTHER BACTERIAL STRAINS
Purpose
Experiment 1 demonstrated stability of bacterial ATP in the AO of a urine sample infected
with E. coli when the ATP is extracted, diluted, and stored for 2.5 hours at room temperature
or lower. This experiment reexamines the problem using urines inoculated with organisms
from reference strains of E. coli, Klebsiella, Enterobacter, Enterococcus, S. aureus, S. epider-
midis, P. mirabilis, and Pseudomonas and a storage period extended to 5 hours.
Procedure
1. Inoculate 4.5 ml of urine with an overnight growth of a reference strain organism in
TSB to achieve 107 organisms/ml.
2. Centrifuge at 8,000 RCF X G for 15 minutes at 4°C.
3. Reconstitute pellet in 5.0 ml TSB; preincubate 0.5 hour.
4. Pipette 0.5-ml aliquots into four tubes for each reference strain:
a. Refrigerate tubes b for 5 hours.
b. Incubate tubes c for 5 hours at 37°C.
c. Add apyrase, HNO3, and H2 O to tubes a and d.
1. Hold tubes a at room temperature for 5 hours.
2. Assay tubes d to serve as true AO 's.
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5. After 5 hours bring tubes b and c to room temperature, and add apyrase, HNO3, and
H20.
6. Assay tubes a, b, and c.
Results
Bacterial ATP in most of those samples stored at refrigerated or higher temperatures with
bacterial cells intact varied considerably from the original AQ level: summing ATP levels of
similar magnitude indicates a trend of decay in tubes b and a trend of growth in tubes c. Good
correlation is shown between the AO and those samples from which the bacterial ATP has
been extracted, diluted, and held at room temperature for 5 hours: summing ATP levels of
similar magnitude indicates a trend of stability in tubes a.
Although the A0 's for S. aureus and S. epidermidis are high (perhaps the original overnight
growths were not sufficiently diluted), the relationships between tubes a, b, c, and d are
still valid.
Conclusion
Once the bacteria in a urine sample are lysed by the addition of HNO3 and then diluted in
H2O, the AO may be stored for as long as 5 hours without sacrificing accuracy. This con-
clusion holds for all eight reference strains (see table B-2).
Table B-2
Results of Experiment 2- Stability of A0 After Extraction,
Dilution, and a 5-hour Incubation Period
Ui , Pseudomonas
U2 Enterococcus
Us P mirabilis
114 S epidermidis
Us S aureus
U6 Klebsiella
117 Enterobacter
Us E coh
Totals
U control
(uninfected)
AO
(light units)
2.75 x 10?
7.53
 x 107
4.05 x 107
3.10 x 108
2.15
 x 109
9. 76 x 107
4.21 x 107
5.20 x 107
3.35 x 108
1.90 x 105
Tube a Room
Temperature
2.89 x 107
7. 52 x 107
4.67 x 107
3.42 x 108
2.55 x 109
8.76 x 107
3.96 x 107
5. 70 x 107
3.35 x 108
3.04 x 105
Tube b
Refrigerated
2 .59x 107
4.77 x 107
2. 91 x 107
3.72 x 108
1.87 xlO9
6.16 x 107
3.23 x lO 7
5.49 y 107
2. 52
 x 108
5.65 x 105
Tube c 37°C
9.49 x 108
7. 65 x 108
2. 72
 x 109
2.09 x 109
8.35 x 108
7. 56 x 108
1.38 x lO 9
1.19 x lO 9
7.76 xlO 9
3.49 xlO5
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EXPERIMENT 3: KANAMYCIN AND STREPTOMYCIN
Purpose
The purpose of this experiment is to determine the lowest concentration of kanamycin and
streptomycin that will give sensitivities at 2.5 hours in agreement with Kirby-Bauer results
! for broths infected with Klebsiella, Enterobacter, Enterococcus, S. aureus, S. epidermidis, P.
mirabilis, orPseudomonas. The lowest possible antibiotic concentration is'preferred in the
luciferase assay because it offers a greater degree of discrimination between sensitivity and
resistance, and because the more highly concentrated antibiotic might enhance the occurrence
of false sensitivites.
Procedure
1. Inoculate 5 ml of TSB with an. overnight growth of a reference organism in TSB to achieve
106 organisms/ml.
2. Preincubate 0.5 hour. >
3. Pipette 0.45 ml aliquots of sample and add 0.05 ml of antibiotic to achieve these final
concentrations:
/
kanamycin (Kj) = 25
kanamycin (K2 ) = 15
kanamycin (K3) = 6
streptomycin (Sj) = 15/ug/nil
streptomycin (S2)-= 10/ug/ml
streptomycin (S3) = 6 ng/ml
4. Prepare AO and!A2 5 controls with sterile distilled H2O instead of antibiotic.
5. Extract and assay AQ immediately (as described in Appendix B, Procedure 2).
6. Incubate remaining samples at 37°C for 2.5 hours.
7. Extract and assay samples.
Results
1. No concentration of kanamycin gave results in agreement with Kirby-Bauer for S.
epidermidis.
2. Kj and K2 gave 100-percent agreement with Kirby-Bauer for the other six organisms.
3. K3 gave false-resistant results for two of those six organisms.
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4. Sj and S2 gave 100-percent agreement with Kirby-Bauer for all seven organisms.
5. S3 gave false-resistant results for two of the seven organisms.
Conclusions
The lowest concentration of kanamycin that will give sensitivities at 2.5 hours that agree with
Kirby-Bauer results for six of the organisms tested (no concentration of the antibiotic was
shown to work in the case of 5. epidermidis) is 15 pig/ml.
The lowest concentration of streptomycin that will give accurate sensitivities for all seven
organisms tested is 10 jug/ml (see table B-3).
EXPERIMENT 4: LONG CENTRIFUGATION VERSUS NONCONCENTRATED
PROCEDURE WITHOUT MALIC ACID
Purpose
The Long Centrifugation procedure, used to detect and quantitate bacterial ATP in a urine
sample, is described in Procedure 1 of this appendix. This determination is necessary in order
to prepare an inoculum of about 106 bacteria/ml to initiate subsequent antibiotic suscepti-
bility testing also by ATP assays. Assays in the susceptibility test, however, involve a different,
less specific assay, the nonconcentrated procedure without malic acid. Before an inoculum
can be prepared for susceptibility testing, the disparity between values obtained by the two
procedures for a given sample must be taken into account. This experiment seeks to establish
that disparity by inoculating urines with given levels of bacteria and comparing ATP levels
obtained by each method.
Procedure
1. Pipette 12 ml of urine into three tubes.
2. Inoculate tube a with 3 X 106 bacteria/ml
tube b with 1 X 107 bacteria/ml
tube c with 1 X 108 bacteria/ml
(diluted from overnight growths of four reference strains in TSB).
3. Centrifuge at 8,000 RCF X G for 15 minutes at 4°C.
4. Reconstitute with 1.2 ml TSB.
5. From tubes a, b, and c pipette 1.0 ml for Long Centrifugation procedure.
a. Add 1.0 ml of apyrase (10 mg/ml 0.03 M CaCl2 - 0.6 percent TX), 4.5 ml 0.9
percent Normal saline, and 0.02 ml of 6.0 percent TX to 1.0 ml sample.
Vortex and wait 15 minutes.
b. Add 1.0 ml 0.25 M malic acid, vortex, and centrifuge at 8,000 RCF X G for 15
minutes at 4°C. Invert and drain 5 minutes.
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Table B-3
Results for Experiment 3: Sensitivity of Seven Organisms to Three
Concentrations of Kanamycin and Streptomycin
ATP Index IndexInterpretation
KB
Interpretation ATP Index
Index
Interpretation
KB
Interpretation
Klebsiella 2 P mirabihs
AO
A2 .5
Kl
K2
K3
AO
A2.5
Si
S2
S3
6 93 x 107
9. 62 x 108
1.69 x 107
1 57 x 107
1 89 x 108
7.60 x lO 7
1 36 x 109
1.33 x 108
4.23 x 108
8. 07
 x 108
-0.06
-0.06
-0.13
+0.04
+0.27
+0.57
S
S
R
S
R
R
S
S
S
I
I
I
4.57 x 107
5. 90 x 108
2.40 x 107
3.37 x 107
4.23 x l O 7
4.33 x 107
6.26 x 108
2.60 x 107
3.38 x 107
9. 52 x 107
-0.04
-0.02
-0.01
-0.03
-0 02
+0.09
S
S
S
S
S
R
S
S
S
S
S
S
Enterobacter Enterococcus
AO
A2.5
Kl
K2
K3
AO
A2.5
Si
s2
S3
3. 54 x 107
5. 60 x 108
1.40 x 106
2. 94 x 106
8.95 x 107
3.15 x 107
5. 23 x 108
3.79 x 106
1. 75 x 107
9.47 x 107
-0.06
-0.06
+0.10
-0.06
-0.03
+0.13
S
S
R
S
S
R
S
S
S
S
S
S
7. 54 x 107
1. 63 x 107
1.74 x 109
1.67 x 109
1. 63 x 109
7.31 x 107
1.79 x 109
1 60 x 109
1.67 x 109
1.44 x 109
+1.07
+1.03
+1.00
+0.89
+0.93
+0 80
R
R
R
R
R
R
R
R
R
R
R
R
S aureus Pseudomonas
AO
A2.5
Kl
K2
K3
AO
A2.5
Si
S2
S3
1.77 x 106
4. 84 x 107
2.54 x 106
2.33 x lO 6
2. 56 x 106
1.84 x 106
4. 70 x 107
7. 63 x 105
6. 83 x 105
1. 91 x 106
+0.02
+0.01
+0.02
-0.02
-0.39
+0.00
S
S
S
S
S
S
S
S
S
S
S
S
7 33 x 105
1.97
 x 107
8 27 x 106
2.03 x 107
2. 72 x 107
8.06 x 105
2.61 x 107
2.00 x 107
2.21 , 107
1. 75 « 107
+0.40
+1.03
+1.40
+0.76
+0.84
+0.66
R
R
R
R
R
R
R
R
R
R
R
R
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Table B-3 (Continued)
ATP Index IndexInterpretation
KB
Interpretation ATP Index
Index
Interpretation
KB
Interpretation
S epidermidis
AO
A2. 5
Kl
K2
K3
AO
A2.5
Si
S2
S3
8.35 x 105
5.81 x 106
2. 16 x 106
2.26 x 106
3.00 x 106
7. 79 x 105
5. 63 x 106
5.44 x 106
5. 17 x 106
5.37 x 106
+0.27
+0.29
+0.44
+0.96
+0.90
+0.95
R
R
R
R
R
R
S
S
S
R
R
R
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c. Add 0.2 ml 0.1 N HNO3, vortex, and wait 5 minutes.
Dilute with 0.2 ml sterile, distilled H2O, and vortex.
d. Assay by injecting 0.1 ml final sample into 0.1 ml luciferase-in 0.25 M TRIS,
0.01 MMgSO4,pH8.2.
6. From tubes a, b, and c, pipette 0.05 ml for nonconcentrated procedure without malic acid.
a. Add 0.45 ml of TSB.
b. Incubate 0.5 hour at 37°C.
c. Add 0.1 ml of apyrase (10 mg/ml 0.03 M CaCl2 - 0.6 percent TX), vortex, and
wait 15 minutes.'
d.
 ; Add 0.1 ml 1.5 N HNO3, vortex, and wait 5 minutes.
Dilute with 4.3 ml sterile, distilled H2 O.
e. Assay by injecting'a 0.1-ml sample into 0.1 ml same luciferase.
Results
A linear correlation is shown to exist between the ATPivalues'obtained by the two procedures
for each organism tested (see figure B-l and table B-4). The average slope is approximately
40.
10"
106
I I PROTEUS MIRABILIS
O—O KLEBSIELLA
E COLI
ENTERO8ACTER
I
10" 109
LIGHT UNITS BY LONG CENTRIFUGATION PROCEDURE
Figure B-1 Comparison of the Long Centrifugation procedure and the
Nonconcentrated procedure.
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Table B-4
Results for Experiment 4: Comparison of the Long Centrifugation
Procedure and the Nonconcentrated Procedure
Organism
P mirabihs
Klebsiella
E coll
Enterobacter
Controls
Inoculum size
(bacteria/ml)
3
 X105
1 x 106
1 x lO 7
3 x 105
1 x 106
1 x 107
3 x 105
1 x lO 6
1 x 107
3 x 105
1 x l f l S
1 x 107
—
-
-
Long Centrifugation
Procedure
(light units)
6.05 x 107
2. 59 x 108
1.39 xlO9
1. 38 x 108
2. 93 x 108
1.44 x 109
2 09 x 10®
8 14 x 108
3. 28 x 109
5. 50 x 107
1.95 x 108
2.30 x 109
5. 90 x 105
1 35 x 1C5
2 67 x 105
Nonconcentrated
Procedure
(light units)
2.27 x 106
8.01
 x 106
4. 90 , 107
2.77 x 106
8. 04
 x 106
7.00 x 107
1. 94 x 106
1.19 x 107
7. 79 x 107
1. 90
 x 106
8. 13 x 106
5.06
 x 107
2.98
 x 105
3.60
 X105
3.64 xlO5
Ratio
26.65
32.33
28.37
49 82
36.44
20 57
107.73
68.40
42.10
28.95
23 40
45 45
—
-
-
Average
Ratio
29.12
1
 35 61
72.74
32.60
Conclusions
To estimate bacterial ATP levels in light units that would be obtained by the nonconcentrated
procedure without malic acid after a 30-minute preincubation period, divide the long Centrifu-
gation light-unit value by about 40. This denominator can be used to construct a dilution
schedule (see table 5-4 on page 81) that will ensure the ATP light unit level of the AQ to fall
in the desired range of 1.0 X 10s to 1.0 X 107 light units on the biometer.
For example, if the long-centrifugation value is 6.0 X l O 9 , the nonconcentrated-procedure-
without-malic-acid value will be approximately 1.5 X 108 (6.0 X 109 divided by 40). Diluting
100-fold would achieve an approximate ATP level of 1.5 X 106. However, since the broth
sample after the initial Centrifugation step in the Long Centrifugation procedure (procedure
1 of Appendix B) represents a 20-fold concentration of the original urine sample, the broth
sample would have to be diluted 20 X 100 or 2000-fold to achieve an ATP light unit level
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of about 106 in the AQ. By examining various long centrifugation values in this manner,
cutoff points can be established that define a range of values for which the sample would
need to be diluted 10-fold, 100-fold, and so on.
Clearly, the final ATP level of the AO reached by these manipulations can only be an approx-
imation. ATP levels in bacteria vary from one organism to the next. In dealing with a urine
of unknown infection, this factor cannot be overcome. Nevertheless, a workable range for
the ATP level can still be achieved.
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